

UNIVERSITY OF PERUGIA DEPARTMENT OF VETERINARY MEDICINE

PhD RESEARCH IN HEALTH AND EXPERIMENTAL VETERINARY SCIENCES: CLINICAL SCIENCE AND VETERINARY DIAGNOSTICS

XXXVII CYCLE

Scientific sector MVET-05/A

INTRA-ARTICULAR TREATMENT WITH TRIAMCINOLONE ACETONIDE AND PLATELET-RICH PLASMA FOR FETLOCK OSTEOARTHRITIS IN THOROUGHBRED RACEHORSES

PhD Candidate:

Dr. Kübra Guidoni

Tutor:

Prof. Antonio Di Meo

Co-tutor:

Prof. Elisabetta Chiaradia

Prof. Francesca Beccati

Doctoral Program Coordinator:

Prof. Beniamino Cenci Goga

Academic Year 2024/2025

1 GENERAL INTRODUCTION

Osteoarthritis (OA), also known as osteoarthrosis or degenerative joint disease, of the diarthrodial joint, is the most significant chronic musculoskeletal disorder in horses and a major animal welfare concern [1]. The metacarpophalangeal (MCP) or fetlock joint is the most commonly affected, leading to lameness, lost training days, and the largest economic losses in the equine industry due to osteoarthritic pain [2-7]. OA is a heterogeneous disease with multiple etiologies, clinical phenotypes, and molecular endotypes, which necessitates differential targeting approaches, opening pathways for the development of effective diseasemodifying OA drugs (DMOADs) [8].

9 Currently, the mainstay of intra-articular therapy focuses on alleviating the clinical signs of the disease through 10 temporary reduction of inflammation, often achieved via corticosteroid (CS) injections [2]. While this 11 approach helps manage musculoskeletal pain and lameness, allowing affected horses to continue training and 12 racing, it does not promote regeneration of the affected joint [9-11]. Triamcinolone acetonide (TA) is the most 13 commonly used corticosteroid in high-motion joints [12]. However, concerns remain about the long-term 14 impact of repetitive use of TA and other corticosteroids on cartilage health [12] as either chondroprotective 15 and chondrotoxic effects in vitro have been reported. [13-16]. As a result, alternative treatments are being 16 explored to minimize repetitive corticosteroid use and support the natural healing processes of the tissues [17].

17 The field of equine regenerative medicine, which includes platelet-rich plasma (PRP), also known as 18 autologous conditioned plasma (ACP), is gaining increasing popularity in the scientific community due to its 19 strategies for the treatment of joint pathologies [9]. Reasons for this increased popularity include the potential 20 to prevent OA progression, reduction in clinical signs and improvement of joint function while reducing the 21 potential of severe adverse event [18]. PRP is an autologous blood product that contains a great number of 22 platelets within a small amount of plasma, but a variable concentration of platelets between individuals due to 23 biological variation [19]. Autologous blood products utilize mechanisms of the natural response to injury, by 24 promoting the production of anti-inflammatory cytokines and release of growth factors [20]. Studies have 25 shown that injecting PRP into equine joints has clinical benefits, including improvement in lameness, synovial 26 effusion, and pain during passive flexion [9,17,21]. Additionally, PRP has been confirmed as a safe option for 27 intra-synovial administration, causing no long-term adverse effects on joint homeostasis, despite a mild early 28 inflammatory response [22,23]. The beneficial effects of PRP are believed to be due to the reduction of 29 inflammatory cytokines and the inhibition of oxidative stress [24,25].

However, despite the prevalence of OA and a phenomenal amount of research is performed each year on OA, yet an exact aetiology has not been elucidated nor an effective treatment discovered [26,27]. Therefore, is necessary to understand the inflammatory cascade behind OA, and to investigate how treatments may affect this cascade. In addition to lameness examination and standard diagnostic procedures, the identification of synovial biomarkers in synovial fluid (SF), to more accurately assess intrasynovial inflammation in cases of joint disease, is an active area of research [28,29]. Biomarkers provide insights into the pathophysiological processes occurring within the joint, offering a non-invasive method to assess disease severity and therapeutic outcomes [30]. The inclusion of synovial biomarkers in OA studies enhances the ability to evaluate the impact
of treatments like intra-articular corticosteroids and biologic products on joint health at a biochemical level,
potentially leading to more targeted and effective therapeutic strategies.

40 The present PhD thesis focused on PRP with the potential of slowing down the disease progression and 41 compared its use to the triamcinolone acetonide since the oldest and most commonly used joint treatments in 42 equine patients. The aim of this study was to investigate the effects of both treatments on chondrocytes, the 43 clinical outcomes in equine patients treated with these products and to investigate their effect on the synovial 44 biomarkers. It was hypothesized that TA and PRP would improve clinical signs of OA and protect the 45 chondrocytes, but PRP would cause stronger anti-inflammatory effect by reducing the concentration of 46 inflammatory cytokines (IL-1β, IL-6), acute phase proteins (APPs), and upregulating the hypoxic condition 47 by activation of hypoxia-inducible factor 1 alpha (HIF1- α) more efficiently than TA treatment.

48

49 REFERENCES

- van Weeren PR, de Grauw JC. Pain in osteoarthritis. Vet Clin North Am Equine Pract. 2010
 Dec;26(3):619-42. doi: 10.1016/j.cveq.2010.07.007. PMID: 21056303.
- Frisbie DD. Synovial joint biology and pathology. In: Auer JA, Stick JA, editors. Equine surgery. 3rd
 edition. St. Louis (MO): Saunders; 2006. p. 1037–55.
- Santschi EM. Articular Fetlock Injuries in Exercising Horses. *Veterinary Clinics of North America - Equine Practice*. 2008;24(1):117-132. doi:10.1016/j.cveq.2007.11.011
- Drum MG, Kawcak CE, Norrdin RW, Park RD, McIlwraith CW, Les CM. Comparison of gross and histopathologic findings with quantitative computed tomographic bone density in the distal third metacarpal bone of racehorses. *Veterinary Radiology and Ultrasound*. 2007;48(6):518-527.
 doi:10.1111/j.1740-8261.2007.00289.x
- 5. Stover SM. The epidemiology of thoroughbred racehorse injuries. *Clinical Techniques in Equine Practice*. 2003;2(4):312-322. doi:10.1053/j.ctep.2004.04.003
- 6. Cruz AM, Hurtig MB. Multiple Pathways to Osteoarthritis and Articular Fractures: Is Subchondral Bone
 63 the Culprit? *Veterinary Clinics of North America Equine Practice*. 2008;24(1):101-116.
 64 doi:10.1016/j.cveq.2007.12.001
- 65 7. Cantley CEL, Firth EC, Delahunt JW, Pfeiffer DU, Thompson KG. Naturally occurring osteoarthritis in
 66 the metacarpophalangeal joints of wild horses. *Equine Vet J.* 1999;31(1):73-81. doi:10.1111/j.204267 3306.1999.tb03794.x
- Mobasheri, A.; Thudium, C.S.; Bay-Jensen, A.C.; Maleitzke, T.; Geissler, S.; Duda, G.N.; Winkler, T.
 Biomarkers for osteoarthritis: Current status and future prospects. Best. Pract. Res. Clin. Rheumatol.
 2023, 37, 101852. [CrossRef] [PubMed]Broeckx S, Zimmerman M, Crocetti S, et al. Regenerative

- therapies for equine degenerative joint disease: A preliminary study. *PLoS One*. 2014;9(1).
 doi:10.1371/journal.pone.0085917
- 9. Broeckx S, Zimmerman M, Crocetti S, et al. Regenerative therapies for equine degenerative joint
 disease: A preliminary study. *PLoS One*. 2014;9(1). doi:10.1371/journal.pone.0085917
- 75 10. Caron JP. Intra-articular injections for joint disease in horses. Vet Clin North Am Equine Pract
 76 2005;21:559–73.
- 11. Whitton RC, Jackson MA, Campbell AJD, et al. Musculoskeletal injury rates in Thoroughbred
 racehorses following local corticosteroid injection. *Veterinary Journal*. 2014;200(1):71-76.
 doi:10.1016/j.tvjl.2013.09.003
- Ferris DJ, Frisbie DD, McIlwraith CW, et al. Current joint therapy usage in equine practice: *Equine veterinary journal* 2011;43:530-535.
- Dechant JE, Baxter GM, Frisbie DD, et al. Effects of dosage titration of methylprednisolone acetate and
 triamcinolone acetonide on interleukin-1-conditioned equine articular cartilage explants in vitro. *Equine veterinary journal* 2003;35:444-450
- Schaefer EC, Stewart AA, Durgam SS, et al. Effects of sodium hyaluronate and triamcinolone acetonide
 on glucosaminoglycan metabolism in equine articular chondrocytes treated with interleukin-1. *American journal of veterinary research* 2009;70:1494-1501.
- Sandler EA, Frisbie DD, McIlwraith CW. A dose titration of triamcinolone acetonide on insulin-like
 growth factor-1 and interleukin-1-conditioned equine cartilage explants. *Equine veterinary journal* 2004;
 36: 58-63.
- 91 4. Dechant JE, Baxter GM, Frisbie DD, et al. Effects of dosage titration of methylprednisolone acetate and
 92 triamcinolone acetonide on interleukin-1-conditioned equine articular cartilage explants in vitro. *Equine* 93 *veterinary journal* 2003;35:444-450
- Schaefer EC, Stewart AA, Durgam SS, et al. Effects of sodium hyaluronate and triamcinolone acetonide
 on glucosaminoglycan metabolism in equine articular chondrocytes treated with interleukin-1. *American journal of veterinary research* 2009;70:1494-1501.
- 97 6. Sandler EA, Frisbie DD, McIlwraith CW. A dose titration of triamcinolone acetonide on insulin-like
 98 growth factor-1 and interleukin-1-conditioned equine cartilage explants. *Equine veterinary journal* 2004;
 99 36: 58-63.
- Dechant JE, Baxter GM, Frisbie DD, et al. Effects of dosage titration of methylprednisolone acetate and
 triamcinolone acetonide on interleukin-1-conditioned equine articular cartilage explants in vitro. *Equine veterinary journal* 2003;35:444-450
- Schaefer EC, Stewart AA, Durgam SS, et al. Effects of sodium hyaluronate and triamcinolone acetonide
 on glucosaminoglycan metabolism in equine articular chondrocytes treated with interleukin-1. *American journal of veterinary research* 2009;70:1494-1501.

- Sandler EA, Frisbie DD, McIlwraith CW. A dose titration of triamcinolone acetonide on insulin-like
 growth factor-1 and interleukin-1-conditioned equine cartilage explants. *Equine veterinary journal* 2004;
 36: 58-63.
- 10. Dechant JE, Baxter GM, Frisbie DD, et al. Effects of dosage titration of methylprednisolone acetate and
 triamcinolone acetonide on interleukin-1-conditioned equine articular cartilage explants in vitro. *Equine veterinary journal* 2003;35:444-450
- 112 11. Schaefer EC, Stewart AA, Durgam SS, et al. Effects of sodium hyaluronate and triamcinolone acetonide
 on glucosaminoglycan metabolism in equine articular chondrocytes treated with interleukin-1. *American journal of veterinary research* 2009;70:1494-1501.
- 115 12. Sandler EA, Frisbie DD, McIlwraith CW. A dose titration of triamcinolone acetonide on insulin-like
 116 growth factor-1 and interleukin-1-conditioned equine cartilage explants. *Equine veterinary journal* 2004;
 117 36: 58-63.
- 13. Dechant JE, Baxter GM, Frisbie DD, et al. Effects of dosage titration of methylprednisolone acetate and
 triamcinolone acetonide on interleukin-1-conditioned equine articular cartilage explants in vitro. *Equine veterinary journal* 2003;35:444-450
- 14. Schaefer EC, Stewart AA, Durgam SS, et al. Effects of sodium hyaluronate and triamcinolone acetonide
 on glucosaminoglycan metabolism in equine articular chondrocytes treated with interleukin-1. *American journal of veterinary research* 2009;70:1494-1501.
- 124 15. Sandler EA, Frisbie DD, McIlwraith CW. A dose titration of triamcinolone acetonide on insulin-like
 125 growth factor-1 and interleukin-1-conditioned equine cartilage explants. *Equine veterinary journal* 2004;
 126 36: 58-63.
- 127 16. Dragoo JL, Danial CM, Braun HJ, Pouliot MA, Kim HJ. The chondrotoxicity of single-dose
 128 corticosteroids. Knee Surg Sports Traumatol Arthrosc. 2012 Sep;20(9):1809-14. doi: 10.1007/s00167129 011-1820-6. Epub 2011 Dec 21. PMID: 22186921.
- 17. Pichereau F, Décory M, Cuevas Ramos G. Autologous platelet concentrate as a treatment for horses with
 refractory fetlock osteoarthritis. *J Equine Vet Sci.* 2014;34(4):489-493. doi:10.1016/j.jevs.2013.10.004
- 132 18. Zaffagnini S, Andriolo L, Boffa A, Poggi A, Cenacchi A, Busacca M, Kon E, Filardo G, Di Martino A.
 133 Microfragmented Adipose Tissue Versus Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis:
 134 A Prospective Randomized Controlled Trial at 2-Year Follow-up. Am J Sports Med. 2022
 135 Sep;50(11):2881-2892. doi: 10.1177/03635465221115821. Epub 2022 Aug 19. PMID: 35984721.
- Rahman, E.; Rao, P.; Abu-Farsakh, H.N.; Thonse, C.; Ali, I.; Upton, A.E.; Baratikkae, S.Y.; Carruthers,
 J.D.A.; Mosahebi, A.; Heidari, N.; et al. Systematic Review of Platelet-Rich Plasma in Medical and
 Surgical Specialties: Quality, Evaluation, Evidence, and Enforcement. J. Clin. Med. 2024, 13, 4571.
 https://doi.org/10.3390/jcm13154571
- 140 20. Brossi PM, Moreira JJ, Machado TS, Baccarin RY. Platelet-rich plasma in orthopedic therapy: a
- 141 comparative systematic review of clinical and experimental data in equine and human musculoskeletal

- lesions. BMC Vet Res. 2015 Apr 22;11:98. doi: 10.1186/s12917-015-0403-z. PMID: 25896610;
 PMCID: PMC4449579.
- 144 21. Perrone G, Lastra Y, González C, et al. Treatment With Platelet Lysate Inhibits Proteases of Synovial
 145 Fluid in Equines With Osteoarthritis. *J Equine Vet Sci.* 2020;88. doi:10.1016/j.jevs.2020.102952
- 146 22. Textor JA, Tablin F. Intra-Articular Use of a Platelet-Rich Product in Normal Horses: Clinical Signs and
 147 Cytologic Responses. *Veterinary Surgery*. 2013;42(5):499-510. doi:10.1111/j.1532-950X.2013.12015.x
- Paula A, Moraes L, Moreira JJ, et al. Article Short-and Long-Term Effects of Platelet-Rich Plasma upon
 Healthy Equine Joints: Clinical and Laboratory Aspects. a survey of veterinarians 2009
- 150 24. Tohidnezhad M, Bayer A, Rasuo B, et al. Platelet-Released Growth Factors Modulate the Secretion of
 151 Cytokines in Synoviocytes under Inflammatory Joint Disease. *Mediators Inflamm*. 2017;2017.
 152 doi:10.1155/2017/1046438
- 153 25. Sadoghi P, Lohberger B, Aigner B, et al. Effect of platelet-rich plasma on the biologic activity of the
 154 human rotator-cuff fibroblasts: A controlled in vitro study. *Journal of Orthopaedic Research*.
 155 2013;31(8):1249-1253. doi:10.1002/jor.22360
- 156 26. Kidd, J.A., Fuller, C. and Barr, A.R.S. (2001), Osteoarthritis in the horse. Equine Veterinary Education,
 13: 160-168. <u>https://doi.org/10.1111/j.2042-3292.2001.tb00082.x</u>
- 158 27. Juhász KZ, Hajdú T, Kovács P, Vágó J, Matta C, Takács R. Hypoxic Conditions Modulate
 159 Chondrogenesis through the Circadian Clock: The Role of Hypoxia-Inducible Factor-1α. Cells. 2024
 160 Chondrogenesis through the Line Conduction Physics (Physics Physics Physics
- 160 Mar 14;13(6):512. doi: 10.3390/cells13060512. PMID: 38534356; PMCID: PMC10969332.
- 161 28. Ribera T, Monreal L, Delgado MA, et al. Synovial fluid D-dimer concentration in horses with
 162 osteochondritis dissecans and osteo- arthritis. Vet Comp Orthop Traumatol 2013;1:54–60.
- 29. Boland L, Danger R, Cabon Q, et al. MMP-2 as an early synovial biomarker for cranial cruciate
 ligament disease in dogs. Vet Comp Orthop Traumatol 2014;3:210–5.
- 165 30. Loeser, R.F. (2006), Molecular mechanisms of cartilage destruction: Mechanics, inflammatory
 166 mediators, and aging collide. Arthritis & Rheumatism, 54: 1357-1360. <u>https://doi.org/10.1002/art.21813</u>
- 167
- 168

169 THE COMBINED USE OF TRIAMCINOLONE AND PLATELET-RICH PLASMA IN EQUINE 170 METACARPOPHALANGEAL JOINT OSTEOARTHRITIS TREATMENTS: AN IN VIVO AND IN 171 VITRO STUDY.

172 Abstract

173 Intra-articular corticosteroids, such as triamcinolone acetonide (TA) help reduce pain related to osteoarthritis 174 (OA), but they may impair cartilage metabolism. In contrast, platelet-rich plasma (PRP) therapy, a regenerative 175 therapy, has shown potential to promote healing and regeneration of articular cartilage. This study investigates 176 the effects of combining PRP with TA to treat osteoarthritis in racehorses. The study proposes that PRP

177 injection following TA treatment could reduce side effects and improve treatment outcomes. Firstly, in vitro 178 study, chondrocytes were exposed to different TA concentrations, with or without PRP. TA dramatically 179 reduced chondrocyte viability, however, this was prevented by the addition of PRP, which also increased cell 180 proliferation. In the in vivo study, 32 racehorses with metacarpophalangeal (MCP) joint OA were separated 181 into two groups: one received only TA, while the other received TA followed by PRP. After one week since 182 the last treatment, both groups demonstrated improved flexion assessments, but by the second week, the 183 TA+PRP group had reduced lameness and flexion scores, showing a longer-term effect. In conclusion, 184 combining PRP with TA could enhance chondrocyte viability and provide a better long-term therapeutic option 185 for treating OA in racehorses. Further trials are required to thoroughly assess this technique's safety and 186 efficacy.

187

188 1. Introduction

Osteoarthritis (OA) in horses is a chronic and degenerative condition with clinical manifestations such as synovitis, varying degrees of lameness, and a progressive loss of joint function. Among equine athletes, the metacarpophalangeal (MCP) joint emerges as a commonly affected joint and can develop both traumatic and degenerative lesions [1]. The impact of OA on the MCP joint holds significant implications for lameness, in particular, resulting in substantial losses in training days and economic burden within the Thoroughbred racehorse industry [2].

195 In equine orthopaedics, the routine intra-articular (IA) administration of corticosteroid as an initial 196 treatment for osteoarthritis is based on the ability of corticosteroids to provide short-term symptomatic relief, 197 provide potent anti-inflammatory, and improve joint mobility, reduce lameness and joint effusion in horses 198 with synovitis and osteoarthritis [3,4]. Among various corticosteroids, triamcinolone acetonide (TA) is the 199 most widely used due to its medium duration of action which has been associated with beneficial effects on 200 articular cartilage [3,5-8]. However, several studies have also identified potential detrimental effects of 201 corticosteroids on articular cartilage composition and morphology [7,9,10]. While these negative effects are 202 now known to be related to the type and dose of corticosteroid used, the frequency of repeated administration 203 and joint loading after injection, it does imply IA corticosteroids should be used judiciously [3,8]. Results of 204 in vitro and in vivo research indicate the use of betamethasone did not show any detrimental effects on articular 205 cartilage, while the methylprednisolone acetonide had deleterious effects. The impact of the TA is still debated 206 as it seems to elicit positive effects in terms of equine cartilage metabolism [11]. Whereas in vitro studies 207 observed that the treatment with TA in cartilage explants was detrimental to cartilage metabolism [6,12]. 208 However, as with all corticosteroids, the potential for unintentional alteration of cartilage metabolism is also 209 present with TA [3].

210 Developing techniques for intra-articular therapies in equine athletes that increase tissue regeneration is 211 critical, with PRP emerging as a potentially regenerative treatment [13]. PRP therapy is becoming more widely 212 accepted [14-16]. PRP contains growth factors capable of stimulating tissue regeneration; these factors 213 promote the proliferation and differentiation of chondrocytes and, possess anti-inflammatory properties [17]. Additionally, PRP has been shown to protect chondrocytes from damage caused by various stressors and drugs 214 215 [18–20]. Moreover, there are growing evidences to support its potential analysic and anti-inflammatory 216 properties, notably in the treatment of OA. PRP injections have been found to reduce pro-inflammatory 217 cytokines and increase anti-inflammatory substances in the joint environment; in addition, this action helps to 218 reduce the overall inflammatory response, which contributes to clinical signs relief in conditions of OA 219 [14,15]. PRP is seen as a cost-effective and low-risk therapeutic option that uses the recipient own biological 220 material to reduce the chance of adverse effects [16]. Several in vitro studies on chondrocytes and tenocytes 221 have shown that corticosteroids have negative effects, while the addition of PRP to these medications 222 significantly reduces cytotoxicity by modulating apoptosis and promoting cell proliferation [19-21]. The 223 combination of TA and growth hormones also showed promise in improving anabolic metabolism in the 224 articular cartilage [22]. Human clinical research examined in the literature reveals that PRP can fill cartilage 225 defects, promote cartilage repair, alleviate OA symptoms, and improve joint function, all while maintaining 226 an acceptable safety profile [23]. To the authors' knowledge, very limited information exists regarding the 227 impact of TA and PRP in equine orthopedics. With the extensive use of corticosteroid injections in equine 228 practice, it is critical to fully understand their effects on the targeted tissues. While these injections have well-229 documented advantages, their related side effects highlight the need for new approaches to long-term joint 230 treatment that try to mitigate potential negative consequences [24].

The aim of this study was to determine how the combination of TA and PRP might improve the clinical signs of MCP joint OA in racehorses. Authors hypothesized that the use of PRP after a single dose of TA may potentially improves the clinical signs of MCP joint OA longer than injection of TA alone. Synovial biomarkers were not investigated in the present study.

235 2. Materials and Methods

236 *2.1. In vitro study*

237 2.1.1. Primary cultures of equine chondrocytes

238 The in vitro study was performed using chondrocytes isolated from metacarpo/metatarsophalangeal joints of 239 6 Thoroughbred horses 4.5 ± 1.3 years old submitted to euthanasia for reasons unrelated to this study and the 240 quality of the biological material was not compromised by their clinical condition. The articular cartilage was 241 harvested post-mortem from the weight-bearing surfaces of the metacarpo/metatarsophalangeal joints, 242 according to Mancini et al. (2017) [25]. Equine tissues were used in accordance with the guidelines of the 243 Animal Care and Use Committee of Perugia University. All the articular surfaces were exposed by making a 244 careful incision around the metacarpo/metatarsophalangeal joint with a sterile scalpel and freeing it from the 245 surrounding tissues. After, macroscopic examination, the cartilage tissues showing structural integrity, 246 consisting in no visible damage, such as tears, cracks, or breaks, and no signs of degenerative changes were 247 collected using scalpel, washed three times in Dulbecco's phosphate-buffered saline (PBS) without Ca2+ and 248 Mg2+, containing penicillin (100 U/mL), streptomycin (100 mg/mL), and amphotericin B (250 µg/mL) 249 (EuroClone, Milan, Italy) and then minced. The minced cartilage was digested with 2.5% of trypsin (Sigma Aldrich, Milan, Italy) at 37°C for 10 min and then with 2mg/ml of collagenase (Sigma Aldrich, Milan, Italy) 250 251 for 16 hours at 37°C. Cells were then collected by using cell strainer 70 m (EuroClone, Milan, Italy), washed 252 and placed in the culture medium consisting of Dulbecco's Modified Eagle Medium (DMEM) supplemented 253 with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 µg/mL streptomycin in a humidified 5% CO2 254 atmosphere at 37°C. The medium was changed every 48h, until cells were split at 90% of confluence. All 255 experiments were conducted using cells at two passages of subculture to minimize alterations in phenotypic 256 drift associated with increased subculturing.

257 2.1.2. PRP preparation

PRP was prepared from whole blood using the double centrifuge method reported by Tognoloni et al. 258 (2023) [26]. Blood was collected from two healthy horses by jugular venipuncture in acid citrate-dextrose 259 260 (ACD) solution. Blood underwent two centrifugation steps, the first at $200 \times g$ for 20 min at 25°C and the 261 second at 1800× g for 10 min at 25°C. The platelet pellet was then re-suspended in a 1 ml volume of plateletpoor plasma to obtain a final platelet concentration of 1×10^6 platelets/ μ L; platelets counts were determined 262 with a hemocytometer (EosBIO, Cervarese Santa Croce, Italy). The leukocyte concentration in the PRP 263 264 preparations was notably low: $0.421 \pm 0.1 \times 10^3/\mu$ L in the *in vitro* study and $0.39 \pm 0.29 \times 10^3/\mu$ L in the *in* 265 vivo study.

266 2.1.3. Cell viability analysis

267 Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 268 (MTT) assay based on the conversion of MTT into a purple-colored formazan products by viable cells. Briefly, 269 cells at density of 10x10³ cells/well were cultured in 96-well plates for 24 hours in medium supplemented with 270 10% FBS. After a washing step in PBS, chondrocyte cells were exposed to 0.25, 0.5, 1, 2 and 4 mg/ml TA 271 (Kenacort, Bristol Mayers Squibb) for 48 hours in presence or in absence of PRP. Control cells were cultured 272 in complete medium alone. After treatments, medium MTT solution (0.5 mg/mL) was added. After 2 hours of 273 incubation, the reaction was stopped by adding DMSO which acts also for solubilizing formazan crystals. The 274 absorbance was measured at 570 nm using a multiplate spectrophotometer (Infinite® 200 Pro-Tecan). The 275 experiments, conducted in triplicate, yielded mean values and standard deviation (SD) from four independent 276 trials. Viability was expressed a percentage of ratio between optical density (OD) of treated cells and OD of 277 control cells.

- 278
- 279 *2.2. In vivo study*

280 2.2.1. Cases Selection

Patients included in this study were stabled at the Jockey Club of Turkey, Ankara Hippodrome, Turkey. The
 inclusion criteria were Thoroughbred racehorses actively in race and training, age between 2 and 5 years-old and

283 at least 2 of the following criteria: unilateral or bilateral MCP joint effusion, pain on passive flexion of the MCP 284 joint, lameness localized to the MCP joint by clinical examination with or without intra-articular diagnostic 285 analgesia. Additionally, radiographic findings consisting with OA of the MCP joint were part of the inclusion 286 criteria. Horses were evaluated by two equine veterinarians, each with over 15 years of experience in the racing 287 industry. All horses underwent a clinical and radiographic examination of the MCP joints. The static examination 288 consisted in the evaluation of joint effusion and the pain at passive flexion. In addition, the evaluation of painful 289 response to passive flexion and joint effusion were graded using a four-point scale ranging from none to severe 290 (0=none, 1=mild, 2=moderate, 3=severe). The dynamic examination included observing the horses trot in a 291 straight line on hard surfaces. Lameness was graded from 0 to 5 using the modified AAEP grading scale [27]. The 292 radiographic examination varied among the cases; however, at least the latero-medial, dorso15° proximal-293 palmarodistal, dorso45° proximolateral-palmarodistomedial oblique, dorso45° proximomedial-palmarodistolateral 294 oblique, flexed lateromedial and flexed dorsopalmar projections of the MCP joint were available [28]. Radiographs were assessed by the jockey club veterinarians and the presence of the following radiographic 295 296 findings were recorded: periarticular osteophytes, capsular enthesophytes, subchondral bone sclerosis/lysis of the 297 proximal phalanx and/or the metacarpal condyle and loss of joint space [28]. Exclusion criteria were horses with 298 bilateral lameness and lameness graded as 4 and 5 on the AAEP grading scale, any type of fracture of the proximal 299 phalanx and of the distal condyle of the metacarpus and any horse that was treated with any IA injection or other 300 systematic anti-inflammatory therapy within 4 weeks before the inclusion in the study.

301 2.2.2. Treatments

302 The horses included in the study were randomly divided into two groups. The randomization was 303 performed with Coin-flip randomization technique. The group TA received one single intra-articular injection 304 of 4 mg (2 mg/ml) of TA (Sinakort-A, Ibrahim Etem) in the affected MCP joint. The group TA+PRP received 305 one single intra-articular injection of 4 mg (2 mg/ml) of TA (Sinakort-A, Ibrahim Etem) followed by one single 306 intra-articular PRP injection one week later. Each joint received 1 ml of a platelet concentration of 1×10^6 307 $PLT/\mu L$. All horses returned progressively to full training within 2-4 weeks following the last treatment. They 308 underwent 24 hours of box rest and avoided high speed exercise for at least 1 week. Follow-up clinical 309 examinations were performed by the same clinicians for all time points. Effusion score and passive flexion 310 score, and lameness evaluations were recorded at 1 week (T1) and 2 weeks (T2) after last treatment. In addition, 311 the clinical outcome was evaluated recording the weeks between T2 and the return of the horse to the Jockey 312 Club Hospital with the same complaint (i.e.: MCP joint disease) including joint effusion, pain at flexion or 313 lameness. Adverse effects after treatments were monitored to check for any occurrence.

314

315 *2.3. Statistical analyses*

The statistical analyses were performed using the statistical software JASP (version 0.18.1, Jasp Team,
 Amsterdam, The Nederland). The quantitative data are expressed as mean ± SD or median and range, as


318 appropriate; nominal data are expressed as prevalence and percentage. For numerical data (age, weeks of the 319 clinical outcome), homoscedasticity of the variables was tested for normality using Shapiro-Wilk test and homogenicity of the variance with Levene test. Cell viability of the in vitro study was evaluated using one-320 321 way analysis of variance (ANOVA) and *post-hoc* Tukey test for multiple comparisons. For the in vivo study, 322 descriptive statistics was applied for age, sex, limb affected (right forelimb or left forelimb), lameness score 323 (baseline, T1, T2), effusion score (baseline, T1, T2), flexion score (baseline, T1, T2) and clinical outcome 324 (weeks). Differences in age and weeks of the clinical outcome between group TA and group TA+PRP were 325 tested using unpaired Student't test or Mann-Whitney U test, as appropriate. Differences in sex and limb 326 affected between the two groups were tested with Chi-squared test. Two-way Kruskal-Wallis test with Dunn's 327 *post-hoc* correction for multiple comparisons were used to test for differences between the groups and time 328 points (baseline, T1 and T2) for effusion score, passive flexion score and lameness score. A p-value < 0.05329 was considered significant. A p-values less than 0.05 were considered as significant.

330 3. Results

331 *3.1 In vitro study*

332 3.1.1. Effect of PRP on chondrocyte culture

Cell viability assessed by (MTT) test after 24 hours of treatment with different concentrations of TA with or without PRP are shown in figure 1. Exclusive use of TA led to a roughly 50% decrease in cell viability, beginning at the minimum dosage of 0.25 mg/ml (p < 0.05) compared to the control and maintaining a gradual decline as the concentration of TA increased to 4 mg/ml dosage vs. control (p < 0.01). In contrast, the combined use of TA with PRP demonstrated a protective effect on cellular viability, reaching average values around 130-140% for all the dosages and showing marked differences compared to TA treatment.



348

Figure 1. Cell viability after the addition of platelet-rich plasma (PRP) to the triamcinolone acetonide (TA) after 24 hours at the treatment dose 0, 0.25, 0.50, 1.0, 2.0 and 4.0 mg/ml, as compared with triamcinolone acetonide alone. Data are the mean \pm SD of four independent experiments performed in triplicates. **p<0.01; ***p<0.001; ****p<0.0001; # p<0.05; # #p<0.001 vs. control (CTRL)

354 3.2 In Vivo study

A total number of 53 MCP joint from 32 horses were included in this study, ranging between 2 and 5 years with a mean \pm SD age of 2.7 \pm 0.9 years. There were 13 females and 19 intact males. Thirty-one joints (right forelimb = 17; left forelimb = 14) from 18 horses were in group TA and twenty-two joints (right forelimb = 12; left forelimb = 10) from 14 horses were in group TA+PRP. In the group TA, from a total of 18 horses, 13 were bilateral and 5 unilateral affected, and in the group TA+PRP, from a total of 14 horses, 8 were bilateral and 6 unilateral affected. There were no differences in age (p = 0.06), sex (p = 0.33), limb affected (p = 0.98) between the group TA and group TA+PRP.

In group TA, 24 out of 31 MCP joints showed effusion; a total of 29 joints had positive responses to the passive flexion and 6 forelimbs were lame in the TA group. In group TA+PRP, 19 out of 22 MCP joint showed effusion; a total of 21 joint had a positive response to the passive flexion and 8 forelimbs were lame. The details of effusion score, passive flexion score and lameness score at each time point in the two groups are summarized in Table 1.

380	Groups	Baseline	T1	<i>T2</i>	p-value*
381		Effusion score (median; range)			
382	Group TA (n=31)	1; 0 – 3	0; 0 – 1 ^a	0; 0 – 2	<.001
	Group TA+PRP (n=22)	2; 0 – 3	0; 0 – 1 ^a	$1; 0 - 1^{b}$	<.001
383	p-value [#]	1.00	1.00	1.00	
384		Passive flexion score (median; range)			
	Group TA (n=31)	2; 0 – 3	0; $0 - 2^a$	1; $0 - 2^{b,c}$	< 0.03
	Group TA+PRP (n=22)	2; 0 – 3	0; $0 - 2^a$	0; 0 – 1 ^b	385 <.001
	<i>p-value</i> [#]	1.00	1.00	<.001	386
		Lameness score (median; range)			
	Group TA (n=31)	0; 0 – 2	0; 0 – 1	0; 0 – 1	1.667
	Group TA+PRP (n=22)	0; 0 – 3	0; 0 – 1 ^a	0; 0 – 1 ^b	0.002 388
	<i>p-value</i> [#]	0.36	1.00	1.00	300
389				I	
390		Weeks of follow-up (median; range)			
391	Group TA (n=31)	4; 4 – 5			na
392	Group TA+PRP (n=22)	7; 6 – 8			na
393 394	<i>p-value</i> [#]	<0.001			
394 395					
395 396		Adverse Effects (prevalence; %)			
390 397		No		Yes	
398	Group TA (n=31)	31 (100%	ó)	0 (0%)	
398 399	Group TA+PRP (n=22)	22 (100%	6)	0 (0%)	
400	p-value [#]	na			

378 Table 1. Median and range of effusion score, passive flexion score, lameness score, weeks of the follow-up and **379** frequencies of adverse effects obtained in group TA and group TA+PRP.

401* p-value of multiple comparison for time; # p-value of the multiple comparison for time. Bold defined402significant differences between group TA and group TA+PRP; a defined significant difference between403T1 and baseline (p<0.05); b defined significant difference between T2 and baseline (p<0.05); c defined404significant difference between T1 and T2 (p<0.05); d defined significant difference between T1 of Group405TA and T2 of Group TA+PRP (p<0.05); na = not applicable.

406

407 There were no significant differences in the effusion score between the groups at each time point (p = 0.77). 408 For both groups, the effusion score at T1 (p < 0.001) was significantly lower than that at baseline; for group 409 TA+PRP, T2 also was significantly lower than that at baseline (p < 0.001). There was no significant difference




Figure 2. Reasons for re-admission to the hospital following the treatments in the TA and TA+PRP groups.
The chart demonstrates the frequency of recurring clinical signs observed during readmission to the hospital,
revealing variations in, effusion, flexion and lameness complaints between the TA and TA+PRP groups.

443 4. Discussion

444 Intra-articular corticosteroids are often used as a first-line treatment for OA affecting equine athletes 445 because they can improve range of motion, and effusion of the MCP joints and relief pain [3]. However, the 446 use of IA corticosteroid is a questionable issue, because they can result in changes of chondrocyte metabolism, 447 cellular toxicity, mitochondrial dysfunction, reactive oxygen species increase and cell death [29,30]. In this 448 study, the effect of combining TA and PRP has been investigated and compared to the effects of TA alone, in 449 vivo and in vitro. Firstly, the potential detrimental effects of TA on equine chondrocytes have been 450 demonstrated in vitro. Indeed, we observed a significant decrease in the viability of equine chondrocytes 451 induced by TA (0.25mg/ml-4 mg/ml), consistent with those demonstrated by other author exposing human 452 chondrocytes to similar [31] and higher concentrations [32,33]. Similar effects have been also observed rabbit 453 chondrocytes [10,34,35] and canine chondrocytes [29,36].

454 In contrast, the combined use of TA and PRP led to an increase in cell viability, indicating a clear 455 protective effect of PRP on the cytotoxicity exerted by TA in vitro. These findings support the results obtained 456 on human chondrocytes exposed to other corticosteroids [19,21]. Additionally, several studies have reported 457 the cytoprotective effects of PRP against the toxicity of various drugs on different fibroblast cell types, 458 including chondrocytes [23,37–40]. For example, PRP increased the cell viability and decreased apoptosis of 459 human rotator cuff tear cells exposed to TA [18,41]. By speculating on our results, it is plausible to hypothesize 460 that PRP can protect chondrocytes by counteracting the pro-oxidant effects of TA. Indeed, it has been reported 461 that TA significantly increases the levels of oxidized glutathione, leading to oxidative stress in human 462 chondrocytes [42]. In contrast, PRP appears to enhance the antioxidant cellular response via the NRF2 pathway 463 [26,44].

464 The results of our in vivo study supported the role of the IA administration of TA+ PRP as able to improve the clinical signs in horses with positive flexion test of the MCP joint and/or lameness due to its anti-465 466 inflammatory activity [45], as well as the synergistic effect of PRP when combined with other drugs [45]. 467 Moreover, these effects could be also related to the ability of PRP in promoting chondrocyte proliferation and 468 cartilage matrix secretion and in stimulating cartilage repair [46,47]. It has been reported that PRP exerts 469 beneficial effects on joint cartilage, synovium, tendon and overall healing processes [48-50]. Specifically, 470 anabolic effects of PRP have been observed in porcine chondrocyte cultures, highlighting its regenerative 471 potential in cartilage tissue [51,52].

472 Synovitis, trauma or insult can lead to activation of the mechanoreceptors [53,54] which in turn can 473 stimulate an inflammatory response with the release of pro-inflammatory cytokines and degradative enzymes 474 (IL-1B and TNF-alpha and MMPs). This further increase the amount of joint swelling and further activating 475 nociceptors and perpetuating pain. All these events result additional osteochondral damage and cartilage 476 degeneration in OA [54]. Acute synovitis is considered the most common problem in equine high-motion joint, 477 as the MCP joint is, contributing to the degradative mechanism of the articular cartilage [55]. For these reasons, 478 it was not surprising that the effusion score in this study group improved after both treatments. Both groups 479 received TA, which is a potent anti-inflammatory drug inhibiting the inflammatory process at all levels [56].

480 The effusion score reduced at T1 compared to the baseline and remained significantly lower at T2 in group 481 TA+PRP. In this study, the use of PRP after the TA did not result in a significant reduction of the synovitis 482 compared to group TA. On the other hand, decreased range of motion and pain on passive flexion, with or 483 without synovial effusion, are thought to indicate an essential underlying condition, which is likely OA [57].

484 A painful response to passive flexion of the joint and lameness are well known clinical signs of pain in 485 horses and human being [58,59]. In our clinical study, a significant reduction in the passive flexion score was 486 demonstrated in both groups. However, in contrast to group TA, the group TA+PRP maintained a lower flexion 487 score compared to the baseline, for a longer time. The group TA+PRP had a longer effect in maintaining a 488 lower flexion scores after 2 weeks (T2), while group TA returned towards the baseline score at T2. Indirectly, 489 this difference demonstrated a shorter analgesic effect in horses treated only with TA compared to that treated 490 by TA followed by PRP. The lameness score was another clinical variable considered. Similarly, despite the 491 low number of horses presenting lameness, a significant decrease in the lameness score was recorded in group 492 TA+PRP at T1 and T2, which was not the case of group TA. These findings may explain the favorable effect 493 of TA+PRP group on lameness score as PRP products were shown to be effective in relieving clinical signs of 494 OA [59,60].

495 In support to the beneficial use of PRP after TA, authors would highlight those horses treated with TA alone returned to the hospital in a shorter time (4.4 weeks on average), compared with horses treated with TA 496 497 and PRP (7.1 weeks on average). Regarding T1 and T2 differences between the groups, it is crucial to note 498 that in the TA group, the assessments at T1 and T2 evaluated the effects of TA alone. In contrast, in the TA + 499 PRP group, T1 and T2 assessments were spaced based on the timing of both TA and PRP administrations. 500 Therefore, the difference in the follow-up weeks may be affected by a slightly different treatment protocols 501 between the two groups. However, this may be attributed to the therapeutic synergy between PRP and TA, 502 offering a promising approach to reducing the adverse effects associated with corticosteroid use in joint 503 treatments [21,61]. The short duration of improvement observed in this study may be related to several 504 contributing factors influencing the recurrence of clinical signs. In the literature, the most common doses of 505 TA administered by equine practitioners range from 5 to 10 mg, with a therapeutic duration rarely exceeding 506 4 to 6 weeks [62-65]. In our study, a dose of 4 mg per joint was used, and the readmission of the horses in the 507 TA group at 4.4-weeks aligns with previous studies [62-65]. Other factors include training strategies, the 508 overall management of the horses, as well as the experience and quality of the staff and riders. Another 509 important point might be the training track surfaces. Thus, horses may be predisposed to recurrence of clinical 510 signs if trained at high intensity on surfaces to which they are not accustomed [65,66]. Additionally, horses 511 with higher athletic demands may experience greater stress on their joints, leading to faster recurrence of issues 512 despite treatment.

513 Moreover, the fact that the flexion score of the horses in the group TA+PRP did not worse in the weeks 514 following the treatment and that the owners of these horses did not complain in training showed that PRP 515 application had a positive effect on pain and longer suppression of the clinical signs. In human studies, it has 516 been demonstrated that PRP improves joint and tissue function, relieves pain and results in favorable clinical 517 outcomes [67,68]. However, there are many studies have shown that PRP is a more suitable method for use in 518 humans than horses. Interestingly, in our study, no adverse effects of IA administration of PRP were recorded, 519 even though it has been reported that this treatment may induce a reaction or transient synovitis [13]. The side 520 effects of the IA administration of PRP are likely to involve the preparation and standardization protocols of 521 PRP and in particular to the leucocyte concentration [69,70]. Overall, the authors suggest that the PRP has a 522 safe profile when used IA and might have a pivotal role in the disease progression due to its ability to protect

523 chondrocytes by reducing the adverse effect of TA.

524 There are some limitations in this study. The first limitation is lack of the use of diagnostic analgesia to 525 determine if the presence of lameness in some horses was due to pain in the MCP joint. From the clinical 526 perspective, it is fair to suggest that the distal limb flexion test is sensitive to examining the MCP joint, but it 527 may be less significant for tissues distal to the joint. Two researchers suggest that the MCP joint is the primary 528 contributor to a positive flexion test [71,72], but clinical signs and radiographic evidence should also be 529 evaluated for a thorough evaluation. For this reason, to avoid bias, more than one criteria was used as inclusion 530 criteria in this study group. The second limitation is that synovial samples were not analysed to assess changes 531 in synovial biomarkers. As a result, this hypothesis remained to be validated experimentally and is the aim of 532 our next study. Third limitation is that in vitro, PRP was added concomitantly with TA-treated chondrocytes, 533 whereas in vivo, PRP was administered one week after TA. This timing also may have influenced the clinical 534 results. However, the in vivo study was conducted on horses with OA symptoms, while the in vitro study used 535 healthy chondrocytes treated with TA. Additionally, tracking the effects of TA for one week on chondrocytes 536 in vitro is challenging, as we observed cytotoxicity even at lower doses. Administering TA prior to PRP 537 allowed us to verify if PRP treatment is more effective in joints with reduced inflammation.

538 Finally, horses with similar pathologies may exhibit individual response to treatment. The therapeutic effects539 may also be influenced by the horses' working discipline and post-treatment exercise protocols.

540 5. Conclusions

541 There are many research going on in the literature use of corticosteroids and PRP, yet in equids use of combined 542 TA and PRP has limited study. The studies evaluating the cytotoxic effects of TA on equine chondrocytes are 543 also limited and controversial. This study is the first to investigate in vitro the potential harmful effects of this 544 corticosteroid on equine cartilage cells and the possible protective effect of PRP when administered together 545 with this drug. The results of the in vivo study suggest a promising strategy to alleviate any adverse effect on 546 chondrocyte viability after the corticosteroid administration, highlighting the potential for mid-term pain relief 547 and reducing lameness through a strategically timed PRP injection. Indirectly, these results could indicate that 548 PRP could elicit a proliferative effect on chondrocytes, even though low, despite the presence of TA. Further 549 clinical trials are crucial for a comprehensive evaluation of the therapeutic potential and safety profile 550 associated with the integration of PRP with triamcinolone in the treatment of osteoarthritis in equine athletes. 551 Multiple PRP injections are likely to lead to better clinical outcome than a single injections. Comparing 552 multiple PRP injections after a single dose of TA versus a single dose of TA alone may reveal changes in outcome [73–75]. However, this need further investigations and also might help a better understanding of the
beneficial effect of PRP injections in the long term.

555

556 References

- 557
- Kawcak, C.E.; McIlwraith, C.W.; Norrdin, R.W.; Park, R.D.; Steyn, P.S. Clinical Effects of Exercise on
 Subchondral Bone of Carpal and Metacarpophalangeal Joints in Horses. *Am J Vet Res* 2000, *61*, 1252–
 1258, doi:10.2460/ajvr.2000.61.1252.
- Neundorf, R.H.; Lowerison, M.B.; Cruz, A.M.; Thomason, J.J.; McEwen, B.J.; Hurtig, M.B.
 Determination of the Prevalence and Severity of Metacarpophalangeal Joint Osteoarthritis in
 Thoroughbred Racehorses via Quantitative Macroscopic Evaluation. *Am J Vet Res* 2010, *71*, 1284–1293,
 doi:10.2460/ajvr.71.11.1284.
- 565 3. Goodrich, L.R.; Nixon, A.J. Medical Treatment of Osteoarthritis in the Horse A Review. *Veterinary*566 *Journal* 2006, *171*, 51–69, doi:10.1016/j.tvjl.2004.07.008.
- de Grauw, J.C.; Visser-Meijer, M.C.; Lashley, F.; Meeus, P.; van Weeren, P.R. Intra-Articular Treatment
 with Triamcinolone Compared with Triamcinolone with Hyaluronate: A Randomised Open-Label
 Multicentre Clinical Trial in 80 Lame Horses. *Equine Vet J* 2016, *48*, 152–158, doi:10.1111/evj.12383.
- 5. Kay, A.T.; Bolt, D.M.; Ishihara, A.; Rajala-Schultz, P.J.; Bertone, A.L. Anti-Inflammatory and Analgesic
 Effects of Intra-Articular Injection of Triamcinolone Acetonide, Mepivacaine Hydrochloride, or Both on
 Lipopolysaccharide-Induced Lameness in Horses. *Am J Vet Res* 2008, *69*, 1646–1654,
 doi:10.2460/ajvr.69.12.1646.
- Dragoo, J.L.; Danial, C.M.; Braun, H.J.; Pouliot, M.A.; Kim, H.J. The Chondrotoxicity of Single-Dose
 Corticosteroids. *Knee Surgery, Sports Traumatology, Arthroscopy* 2012, 20, 1809–1814,
 doi:10.1007/s00167-011-1820-6.
- 577 7. Van Pelt, R.W.; Riley, W.F. Tarsal Hydrarthrosis in the Horse: Response to Intra-Articular Injection of
 578 Synthetic Steroids. *Can Vet J* 1969, *10*, 130–135.
- Frisbie, D.D.; Kawcak, C.E.; Trotter, G.W.; Powers, B.E.; Walton, R.M.; McIlwraith, C.W. Effects of Triamcinolone Acetonide on an in Vivo Equine Osteochondral Fragment Exercise Model. *Equine Vet J* **1997**, *29*, 349–359, doi:10.1111/j.2042-3306.1997.tb03138.x.
- 582 9. Wernecke, C.; Braun, H.J.; Dragoo, J.L. The Effect of Intra-Articular Corticosteroids on Articular
 583 Cartilage: A Systematic Review. *Orthop J Sports Med* 2015, *3*, 1–7, doi:10.1177/2325967115581163.
- Lutfi, A.M.; Kosel, K. Effects of Intra-Articularly Administered Corticosteroids and Salicylates on the
 Surface Structure of Articular Cartilage. *J Anat* 1978, *127*, 393–402.
- 586 11. McIlwraith, C.W. The Use of Intra-Articular Corticosteroids in the Horse: What Is Known on a Scientific
 587 Basis? *Equine Vet J* 2010, *42*, 563–571, doi:10.1111/j.2042-3306.2010.00095.x.

- 588 12. Dechant, J.E.; Baxter, G.M.; Frisbie, D.D.; Trotter, G.W.; McIlwraith, C.W. Effects of Dosage Titration 589 of Methylprednisolone Acetate and Triamcinolone Acetonide on Interleukin-1-Conditioned Equine 590 Articular Cartilage **Explants** in Vitro. Equine Vet J2003, 35, 444-450, 591 doi:10.2746/042516403775600479.
- Textor, J.A.; Tablin, F. Intra-Articular Use of a Platelet-Rich Product in Normal Horses: Clinical Signs
 and Cytologic Responses. *Veterinary Surgery* 2013, 42, 499–510, doi:10.1111/j.1532950X.2013.12015.x.
- 595 14. Dório, M.; Pereira, R.M.R.; Luz, A.G.B.; Deveza, L.A.; de Oliveira, R.M.; Fuller, R. Efficacy of Platelet596 Rich Plasma and Plasma for Symptomatic Treatment of Knee Osteoarthritis: A Double-Blinded Placebo597 Controlled Randomized Clinical Trial. *BMC Musculoskelet Disord* 2021, *22*, doi:10.1186/s12891-021598 04706-7.
- 599 15. Filardo, G.; Kon, E.; Roffi, A.; Di Matteo, B.; Merli, M.L.; Marcacci, M. Platelet-Rich Plasma: Why
 600 Intra-Articular? A Systematic Review of Preclinical Studies and Clinical Evidence on PRP for Joint
 601 Degeneration. *Knee Surgery, Sports Traumatology, Arthroscopy* 2015, *23*, 2459–2474.
- Hur, C.I.; Park, C.; Li, H.; Seon, J.K.; Kim, H.K.; Yoon, T.R.; Song, E.-K. Effect of Autologus PlateletRich Plasma on IL-6, MMP-3 and MCP-1 Expression in Synoviocytes from Osteoarthritic Patients Knees. *Open Journal of Regenerative Medicine* 2014, *03*, 64–72, doi:10.4236/ojrm.2014.33008.
- Bonilla-Gutiérrez, A.F.; López, C.; Carmona, J.U. Regenerative Therapies for the Treatment of
 Tenodesmic Injuries in Horses. *J Equine Vet Sci* 2019, *73*, 139–147.
- Muto, T.; Kokubu, T.; Mifune, Y.; Sakata, R.; Nagura, I.; Nishimoto, H.; Harada, Y.; Nishida, K.; Kuroda,
 R.; Kurosaka, M. Platelet-Rich Plasma Protects Rotator Cuff-Derived Cells from the Deleterious Effects
 of Triamcinolone Acetonide. *Journal of Orthopaedic Research* 2013, *31*, 976–982,
 doi:10.1002/jor.22301.
- Beitzel, K.; McCarthy, M.B.; Cote, M.P.; Apostolakos, J.; Russell, R.P.; Bradley, J.; ElAttrache, N.S.;
 Romeo, A.A.; Arciero, R.A.; Mazzocca, A.D. The Effect of Ketorolac Tromethamine,
 Methylprednisolone, and Platelet-Rich Plasma on Human Chondrocyte and Tenocyte Viability. *Arthroscopy Journal of Arthroscopic and Related Surgery* 2013, 29, 1164–1174,
 doi:10.1016/j.arthro.2013.04.006.
- Baboldashti, N.Z.; Poulsen, R.C.; Franklin, S.L.; Thompson, M.S.; Hulley, P.A. Platelet-Rich Plasma
 Protects Tenocytes From Adverse Side Effects of Dexamethasone and Ciprofloxacin. *Am J Sports Med* **2011**, *39*, 1929–1935, doi:10.1177/0363546511407283.
- 619 21. Durant, T.J.S.; Dwyer, C.R.; McCarthy, M.B.R.; Cote, M.P.; Bradley, J.P.; Mazzocca, A.D. Protective 620 Nature of Platelet-Rich Plasma Against Chondrocyte Death When Combined with Corticosteroids or 621 Local Anesthetics. American Journal of *Sports* Medicine 2017, 45, 218-225, 622 doi:10.1177/0363546516664161.

- Wong, M.W.N.; Tang, Y.Y.N.; Lee, S.K.M.; Fu, B.S.C.; Chan, B.P.; Chan, C.K.M. Effect of
 Dexamethasone on Cultured Human Tenocytes and Its Reversibility by Platelet-Derived Growth Factor. *J Bone Joint Surg Am* 2003, 85, 1914–1920, doi:10.2106/00004623-200310000-00008.
- 626 23. Xie, X.; Zhang, C.; Tuan, R.S. Biology of Platelet-Rich Plasma and Its Clinical Application in Cartilage
 627 Repair. *Arthritis Res Ther* 2014, *16*, 204, doi:10.1186/ar4493.
- 628 24. Palma, H.E.; Gallio, M.; Silva, G.B. da; Cantarelli, C.; Bertolin, K.; Wolkmer, P.; Wergutz, J.; Krause,
- L.M.F.; Krause, A.; Antoniazzi, A.Q.; et al. Comparison of the Effects of Triamcinolone Acetonide or
 Platelet-Rich Plasma on Expression of Extracellular Matrix-Related Genes in Equine Healthy
 Chondrocytes in Vitro. *Ciência Rural* 2019, *49*, doi:10.1590/0103-8478cr20180262.
- 632 25. Mancini, F.; Nannarone, S.; Buratta, S.; Ferrara, G.; Stabile, A.M.; Vuerich, M.; Santinelli, I.; Pistilli, A.;
 633 Chiaradia, E. Effects of Xylazine and Dexmedetomidine on Equine Articular Chondrocytes in Vitro. *Vet*634 *Anaesth Analg* 2017, 44, 295–308, doi:10.1016/j.vaa.2016.04.004.
- 635 26. Tognoloni, A.; Bartolini, D.; Pepe, M.; Di Meo, A.; Porcellato, I.; Guidoni, K.; Galli, F.; Chiaradia, E.
 636 Platelets Rich Plasma Increases Antioxidant Defenses of Tenocytes via Nrf2 Signal Pathway. *Int J Mol*637 *Sci* 2023, *24*, doi:10.3390/ijms241713299.
- 638 27. Committee, A.H.S. *Guide to Veterinary Services for Horse Shows*; 7th ed.; American Association of
 639 Equine Practitioners: Lexington, 1999.
- 640 28. Santschi, E.M. How to Interpret Radiographs of the Fetlock and Pastern Joint of the Young Performance
 641 Horse. *AAEP proc* 2013, *59*, 395–401.
- Sherman, S.L.; Khazai, R.S.; James, C.H.; Stoker, A.M.; Flood, D.L.; Cook, J.L. In Vitro Toxicity of
 Local Anesthetics and Corticosteroids on Chondrocyte and Synoviocyte Viability and Metabolism. *Cartilage* 2015, *6*, 233–240, doi:10.1177/1947603515594453.
- 645 30. Li, Q.; Chen, H.; Li, Z.; Zhang, F.; Chen, L. Glucocorticoid Caused Lactic Acid Accumulation and
 646 Damage in Human Chondrocytes via ROS-Mediated Inhibition of Monocarboxylate Transporter 4. *Bone*647 2022, *155*, doi:10.1016/j.bone.2021.116299.
- Farkas, B.; Kvell, K.; Czömpöly, T.; Illés, T.; Bárdos, T. Increased Chondrocyte Death after Steroid and
 Local Anesthetic Combination. *Clin Orthop Relat Res* 2010, *468*, 3112–3120, doi:10.1007/s11999-0101443-0.
- Tu, Y.; Xue, H.; Francis, W.; Davies, A.P.; Pallister, I.; Kanamarlapudi, V.; Xia, Z. Lactoferrin Inhibits
 Dexamethasone-Induced Chondrocyte Impairment from Osteoarthritic Cartilage through up-Regulation
 of Extracellular Signal-Regulated Kinase 1/2 and Suppression of FASL, FAS, and Caspase 3. *Biochem Biophys Res Commun* 2013, 441, 249–255, doi:10.1016/j.bbrc.2013.10.047.
- Sharma, V.; Sakhalkar, U.; Nadkarni, P.; Mishal, R.; Parandhaman, D.; Vichare, K.; Francis, A.; Khanna,
 M.; Kukreja, M.; Sharma, A. Cytoprotective Effect of Growth Factors Derived From Platelets on
 Corticosteroid-Treated Primary Anterior Cruciate Ligament-Derived Stromal Cells and Chondrocytes. *Cureus* 2024, doi:10.7759/cureus.65566.

- Shapiro, P.S.; Rohde, R.S.; Froimson, M.I.; Lash, R.H.; Postak, P.; Greenwald, A.S. The Effect of Local
 Corticosteroid or Ketorolac Exposure on Histologic and Biomechanical Properties of Rabbit Tendon and
 Cartilage. *HAND* 2007, *2*, 165–172, doi:10.1007/s11552-007-9042-6.
- Albano, M.B.; Skroch, G.P.; Ioshii, S.O.; Grahels, X.S.; de Alencar, P.G.C.; Matias, J.E.F. Computerized
 Photocolorimetric Analysis of the Effects of Intraarticular Betamethasone on the Proteoglycan
 Concentration of Leporine Knee Cartilage Matrix: Influence of the Number of Intraarticular Injections. *Rev Col Bras Cir* 2009, *36*, 256–260.
- Euppayo, T.; Siengdee, P.; Buddhachat, K.; Pradit, W.; Chomdej, S.; Ongchai, S.; Nganvongpanit, K. In
 Vitro Effects of Triamcinolone Acetonide and in Combination with Hyaluronan on Canine Normal and
 Spontaneous Osteoarthritis Articular Cartilage. *In Vitro Cell Dev Biol Anim* 2016, *52*, 723–735,
 doi:10.1007/s11626-016-0022-4.
- Tognoloni, A.; Pellegrini, M.; Di Salvo, A.; Sforna, M.; Cagiola, M.; Seccaroni, M.; Nannarone, S.;
 Beccati, F.; Pressanto, M.C.; Di Meo, A.; et al. Cytotoxicity of Local Anaesthetics and Protective Effects
 of Platelet Rich Plasma on Equine Tenocytes: An in Vitro Study. *Veterinary Journal* 2024, *306*,
 doi:10.1016/j.tvjl.2024.106159.
- 674 38. Yang, J.; Guo, A.; Li, Q.; Wu, J. Platelet-Rich Plasma Attenuates Interleukin-1β-Induced Apoptosis and
 675 Inflammation in Chondrocytes through Targeting Hypoxia-Inducible Factor-2α. *Tissue Cell* 2021, *73*,
 676 doi:10.1016/j.tice.2021.101646.
- Gilbertie, J.M.; Long, J.M.; Schubert, A.G.; Berglund, A.K.; Schaer, T.P.; Schnabel, L. V. Pooled
 Platelet-Rich Plasma Lysate Therapy Increases Synoviocyte Proliferation and Hyaluronic Acid
 Production While Protecting Chondrocytes from Synoviocyte-Derived Inflammatory Mediators. *Front Vet Sci* 2018, 5, doi:10.3389/fvets.2018.00150.
- 681 40. Chiou, C.-S.; Wu, C.-M.; Dubey, N.K.; Lo, W.-C.; Tsai, F.-C.; Tung, T.D.X.; Hung, W.-C.; Hsu, W.-C.;
 682 Chen, W.-H.; Deng, W.-P. Mechanistic Insight into Hyaluronic Acid and Platelet-Rich Plasma-Mediated
 683 Anti-Inflammatory and Anti-Apoptotic Activities in Osteoarthritic Mice. *Aging* 2018, *10*, 4152–4165,
 684 doi:10.18632/aging.101713.
- Muto, T.; Kokubu, T.; Mifune, Y.; Inui, A.; Sakata, R.; Harada, Y.; Takase, F.; Kurosaka, M. Effects of
 Platelet-Rich Plasma and Triamcinolone Acetonide on Interleukin-1ß-Stimulated Human Rotator CuffDerived Cells. *Bone Joint Res* 2016, *5*, 602–609, doi:10.1302/2046-3758.512.2000582.
- 42. Suntiparpluacha, M.; Tammachote, N.; Tammachote, R. Triamcinolone Acetonide Reduces Viability,
 Induces Oxidative Stress, and Alters Gene Expressions of Human Chondrocytes. *Eur Rev Med Pharmacol Sci* 2016, *20*, 4985–4992.
- 43. Tohidnezhad, M.; Varoga, D.; Wruck, C.J.; Brandenburg, L.O.; Seekamp, A.; Shakibaei, M.; Sönmez,
 T.T.; Pufe, T.; Lippross, S. Platelet-Released Growth Factors Can Accelerate Tenocyte Proliferation and
 Activate the Anti-Oxidant Response Element. *Histochem Cell Biol* 2011, *135*, 453–460,
 doi:10.1007/s00418-011-0808-0.

- 44. Jo, C.H.; Lee, S.Y.; Yoon, K.S.; Shin, S. Effects of Platelet-Rich Plasma With Concomitant Use of a
 Corticosteroid on Tenocytes From Degenerative Rotator Cuff Tears in Interleukin 1β-Induced
 Tendinopathic Conditions. *Am J Sports Med* 2017, *45*, 1141–1150, doi:10.1177/0363546516681294.
- 45. Peng, C.; Yang, L.; Labens, R.; Gao, Y.; Zhu, Y.; Li, J. A Systematic Review and Meta-Analysis of the
 Efficacy of Platelet-Rich Plasma Products for Treatment of Equine Joint Disease. *Equine Vet J* 2024, *56*,
 858–869, doi:10.1111/evj.14042.
- Wu, Q.; Yao, X.; Shan, N.; Cai, Y.; Fan, Y. Platelet-Rich Plasma Ameliorates Cartilage Degradation in
 Rat Models of Osteoarthritis via the OPG/RANKL/RANK System. *Folia Histochem Cytobiol* 2024,
 doi:10.5603/fhc.100179.
- 704 47. Zhou, D.; Jang, J.M.; Yang, G.; Ha, H.C.; Fu, Z.; Kim, D.K. A Novel Role of Hyaluronic Acid and
 705 Proteoglycan Link Protein 1 (HAPLN1) in Delaying Vascular Endothelial Cell Senescence. *Biomol Ther*706 (*Seoul*) 2023, *31*, 629–639, doi:10.4062/biomolther.2023.096.
- Xue, Y.; Su, X.; Jiang, M.; Yu, Z.; Yang, H.; Qin, L.; Giannoudis, P. V.; Guo, J.J. Pure Platelet-Rich
 Plasma Facilitates the Repair of Damaged Cartilage and Synovium in a Rabbit Hemorrhagic Arthritis
 Knee Model. *Arthritis Res Ther* 2020, *22*, doi:10.1186/s13075-020-02155-6.
- Kon, E.; Filardo, G.; Di Martino, A.; Marcacci, M. Platelet-Rich Plasma (PRP) to Treat Sports Injuries:
 Evidence to Support Its Use. *Knee Surgery, Sports Traumatology, Arthroscopy* 2011, *19*, 516–527,
 doi:10.1007/s00167-010-1306-y.
- Wang, Z.; Zhu, P.; Liao, B.; You, H.; Cai, Y. Effects and Action Mechanisms of Individual Cytokines
 Contained in PRP on Osteoarthritis. *J Orthop Surg Res* 2023, *18*, 713, doi:10.1186/s13018-023-04119-3.
- 715 51. Akeda, K.; An, H.S.; Okuma, M.; Attawia, M.; Miyamoto, K.; Thonar, E.J.M.A.; Lenz, M.E.; Sah, R.L.;
- Masuda, K. Platelet-Rich Plasma Stimulates Porcine Articular Chondrocyte Proliferation and Matrix
 Biosynthesis. *Osteoarthritis Cartilage* 2006, *14*, 1272–1280, doi:10.1016/j.joca.2006.05.008.
- 52. Lippross, S.; Moeller, B.; Haas, H.; Tohidnezhad, M.; Steubesand, N.; Wruck, C.J.; Kurz, B.; Seekamp,
 A.; Pufe, T.; Varoga, D. Intraarticular Injection of Platelet-Rich Plasma Reduces Inflammation in a Pig
 Model of Rheumatoid Arthritis of the Knee Joint. *Arthritis Rheum* 2011, *63*, 3344–3353,
 doi:10.1002/art.30547.
- Mathiessen, A.; Conaghan, P.G. Synovitis in Osteoarthritis: Current Understanding with Therapeutic
 Implications. *Arthritis Res Ther* 2017, *19*, 18, doi:10.1186/s13075-017-1229-9.
- van Weeren, P.R.; de Grauw, J.C. Pain in Osteoarthritis. *Vet Clin North Am Equine Pract* 2010, *26*, 619–
 642, doi:10.1016/j.cveq.2010.07.007.
- 55. McIlwraith, C.W. From Arthroscopy to Gene Therapy-30 Years of Looking in Joints. In Proceedings of
 the American Association of Equine Practitioners, Seattle, 2005.
- 56. Laufer, S.; Greim, C.; Bertsche, T. An In-Vitro Screening Assay for the Detection of Inhibitors of
 Proinflammatory Cytokine Synthesis: A Useful Tool for the Development of New Antiarthritic and
 Disease Modifying Drugs. *Osteoarthritis Cartilage* 2002, *10*, 961–967, doi:10.1053/joca.2002.0851.

- 731 57. Verschooten, F.; Verbeeck, J. Flexion Test of the Metacarpophalangeal and Interphalangeal Joints and
 732 Flexion Angle of the Metacarpophalangeal Joint in Sound Horses. *Equine Vet J* 1997, *29*, 50–54,
 733 doi:10.1111/j.2042-3306.1997.tb01636.x.
- Find Strategy Field Strateg
- 59. Bertone, A.L.; Ishihara, A.; Zekas, L.J.; Wellman, M.L.; Lewis, K.B.; Schwarze, R.A.; Barnaba, A.R.;
 Schmall, M.L.; Kanter, P.M.; Genovese, R.L. Evaluation of a Single Intra-Articular Injection of
 Autologous Protein Solution for Treatment of Osteoarthritis in Horses. *Am J Vet Res* 2014, *75*, 141–151,
 doi:10.2460/ajvr.75.2.141.
- 741 60. Tyrnenopoulou, P.; Diakakis, N.; Karayannopoulou, M.; Savvas, I.; Koliakos, G. Evaluation of Intra742 Articular Injection of Autologous Platelet Lysate (PL) in Horses with Osteoarthritis of the Distal
 743 Interphalangeal Joint. *Veterinary Quarterly* 2016, *36*, 56–62, doi:10.1080/01652176.2016.1141257.
- 61. Camurcu, Y.; Sofu, H.; Ucpunar, H.; Kockara, N.; Cobden, A.; Duman, S. Single-Dose Intra-Articular
 Corticosteroid Injection Prior to Platelet-Rich Plasma Injection Resulted in Better Clinical Outcomes in
 Patients with Knee Osteoarthritis: A Pilot Study. *J Back Musculoskelet Rehabil* 2018, *31*, 603–610,
 doi:10.3233/BMR-171066.
- 52. Smith, L.C.R.; Wylie, C.E.; Palmer, L.; Ramzan, P.H.L. A Longitudinal Study of Fractures in 1488
 Thoroughbred Racehorses Receiving Intrasynovial Medication: 2006–2011. Equine Vet J 2018, 50, 774–
 750 780, doi:10.1111/evj.12833.
- Ferris, D.J.; Frisbie, D.D.; McIlwraith, C.W.; Kawcak, C.E. Current Joint Therapy Usage in Equine
 Practice: A Survey of Veterinarians 2009. Equine Vet J 2011, 43, 530–535, doi:10.1111/j.20423306.2010.00324.x.
- Kawcak, C.E.; Norrdin, R.W.; Frisbie, D.D.; Trotter, G.W.; Mcilwraith, C.W. Effects of Osteochondral
 Fragmentation and Intra-Articular Triamcinolone Acetonide Treatment on Subchondral Bone in the
 Equine Carpus. Equine Vet J 1998, 30, 66–71, doi:10.1111/j.2042-3306.1998.tb04090.x.
- 757 65. Pieter H. L. Ramzan The Racehorse: A Veterinary Manual; 2nd ed.; Taylor & Francis Ltd, 2023.
- 66. Lindner, A.; Dingerkus, A. Incidence of Training Failure among Thoroughbred Horses at Cologne,
 Germany. Prev Vet Med 1993, 16, 85–94, doi:https://doi.org/10.1016/0167-5877(93)90078-8.
- 760 67. Khoury, M.A.; Chamari, K.; Tabben, M.; Alkhelaifi, K.; Papacostas, E.; Marín Fermín, T.; Laupheimer,
- M.; D Hooghe, P. Knee Osteoarthritis: Clinical and MRI Outcomes After Multiple Intra-Articular
 Injections With Expanded Autologous Adipose-Derived Stromal Cells or Platelet-Rich Plasma. *Cartilage*2023, 14, 433–444, doi:10.1177/19476035231166127.
- 68. Elksniņš-Finogejevs, A.; Vidal, L.; Peredistijs, A. Intra-Articular Platelet-Rich Plasma vs Corticosteroids
 in the Treatment of Moderate Knee Osteoarthritis: A Single-Center Prospective Randomized Controlled
 Study with a 1-Year Follow Up. *J Orthop Surg Res* 2020, *15*, doi:10.1186/s13018-020-01753-z.

- McCarrel, T.M.; Minas, T.; Fortier, L.A. Optimization of Leukocyte Concentration in Platelet-Rich
 Plasma for the Treatment of Tendinopathy. *J Bone Joint Surg Am* 2012, *94*, e143(1-8),
 doi:10.2106/JBJS.L.00019.
- 770 70. Braun, H.J.; Kim, H.J.; Chu, C.R.; Dragoo, J.L. The Effect of Platelet-Rich Plasma Formulations and
 771 Blood Products on Human Synoviocytes: Implications for Intra-Articular Injury and Therapy. *Am J Sports*772 *Med* 2014, *42*, 1204–1210, doi:10.1177/0363546514525593.
- 773 71. Meijer, M.C.; Busschers, E.; Van Weeren, P.R. Which Joint Is Most Important for the Positive Outcome
 774 of a Flexion Test of the Distal Forelimb of a Sound Horse? *Equine Vet Educ* 2001, *13*, 319–323,
 775 doi:10.1111/j.2042-3292.2001.tb00121.x.
- 776 72. Kearney, C.M.; Weeren, P.R. Van; Cornelissen, B.P.M.; Boon, P. Den; Brama, P.A.J. Which Anatomical
 777 Region Determines a Positive Flexion Test of the Distal Aspect of a Forelimb in a Nonlame Horse? *Equine*778 *Vet J* 2010, *42*, 547–551, doi:10.1111/j.2042-3306.2010.00075.x.
- 779 73. Uslu Güvendi, E.; Aşkin, A.; Güvendi, G.; Koçyiğit, H. Comparison of Efficiency between Corticosteroid
 780 and Platelet Rich Plasma Injection Therapies in Patients with Knee Osteoarthritis. *Arch Rheumatol* 2018,
 781 33, 273–281, doi:10.5606/ArchRheumatol.2018.6608.
- 74. Görmeli, G.; Görmeli, C.A.; Ataoglu, B.; Çolak, C.; Aslantürk, O.; Ertem, K. Multiple PRP Injections
 783 Are More Effective than Single Injections and Hyaluronic Acid in Knees with Early Osteoarthritis: A
 784 Randomized, Double-Blind, Placebo-Controlled Trial. *Knee Surgery, Sports Traumatology, Arthroscopy*785 2017, *25*, 958–965, doi:10.1007/s00167-015-3705-6.
- 786 75. Campbell, K.A.; Saltzman, B.M.; Mascarenhas, R.; Khair, M.M.; Verma, N.N.; Bach, B.R.; Cole, B.J.
 787 Does Intra-Articular Platelet-Rich Plasma Injection Provide Clinically Superior Outcomes Compared
 788 With Other Therapies in the Treatment of Knee Osteoarthritis? A Systematic Review of Overlapping
 789 Meta-Analyses. *Arthroscopy* 2015, *31*, 2213–2221, doi:10.1016/j.arthro.2015.03.041.
- 790

791

792

793

794

795

796

797

798

799

800 SYNOVIAL BIOMARKER CHANGES IN OSTEOARTHRITIC HORSES TREATED WITH 801 PLATELET-RICH PLASMA AND TRIAMCINOLONE ACETONIDE.

802

803 Abstract

804 Joint disease, particularly osteoarthritis (OA), is a leading cause of lameness and performance decline in equine 805 athletes. This study aimed to assess the effects of intra-articular injections of platelet-rich plasma (PRP) alone 806 and in combination with triamcinolone acetonide (TA) on the levels of specific OA biomarkers in the synovial 807 fluid (SF) of the fetlock joint. Fourteen horses presenting with unilateral lameness, joint effusion, and pain on 808 flexion were enrolled and divided into two treatment groups: PRP-alone (n=7) and TA+PRP (n=7). The PRP-809 alone group received a single intra-articular injection of PRP, while the TA+PRP group received a PRP 810 injection one week following TA administration. Synovial fluid samples were collected before and after 811 treatment to measure concentrations of eight biomarkers: fibrinogen, haptoglobin, total protein, MMP-2, 812 MMP-9, IL-1β, IL-6, and HIF-1α. Within the TA+PRP group, significant differences were observed in fibrinogen, haptoglobin, and total protein levels at each time point. TA injection initially decreased these 813 814 biomarkers, but subsequent PRP administration restored their levels, except for total protein, which continued 815 to decrease gradually. After PRP injection, a significant difference in total protein concentration was observed 816 between the two groups, with a gradual decline in total protein levels in the TA+PRP group. These findings 817 suggest that PRP alone does not significantly alter biomarker expression, supporting its safety as an intra-818 articular treatment without corticosteroid preconditioning. However, the combination of TA and PRP appeared 819 to have a synergistic effect, potentially promoting controlled inflammation within the joint. Further studies 820 with larger sample sizes and additional time points are recommended to better understand the efficacy of these 821 treatments on synovial biomarkers in OA management.

822

823 1. Introduction

824 Lameness from osteoarthritis (OA) is a leading cause of reduced performance and early retirement in horses, 825 causing significant economic losses due to its high prevalence in racehorses [1-3]. The diagnosis of joint 826 disease is routinely based on physical lameness examination, diagnostic imaging methods and diagnostic 827 arthroscopy and synovial fluid (SF) analyses[4]. Analysis of synovial fluid can aid in finding candidate 828 biomarkers by revealing abnormal metabolic processes to reduce the pathophysiological mechanism of OA, 829 monitor changes in joint tissue metabolism during the progression of OA and also monitor the response to 830 therapy and observe curative effects [5,6]. SF is an alternative approach for determining the effects of 831 therapeutic agents in vivo [7]. However, still have to be fully validated to determine how alterations in 832 biomarkers specifically relate to structural or functional outcomes [8]. Analyses of SF in case of joint disease, 833 show increasing concentrations of proteins compared to physiological conditions [9]. Joint damage induces

the production of cytokines such as- 1β , IL-6 which also trigger the acute phase response and production of acute-phase proteins (APPs) [10,11].

836 IL-6 production is triggered by the release of IL-1 β and is a secondary mediator associated with inflammatory 837 cells, IL-6 is believed to be one of the major factors in joint destruction, being a pleiotropic proinflammatory 838 cytokine which is markedly upregulated at times of tissue inflammation.[12]. The APPs are believed to play 839 major roles in several aspects of the systemic reaction to inflammation and overall regulation of different stages 840 of inflammation [13]. Moderate positive APPs, such as haptoglobin (HP) and fibrinogen (FIB), also play crucial 841 roles, though their increase during inflammation tends to be less pronounced compared to SAA [14]. HP, in 842 particular, has been investigated in various body fluids, including peritoneal fluid in horses with abdominal 843 pain and in serum during experimentally induced arthritis [15,16]. Recent studies have pointed to the potential 844 role of Hp as a marker of inflammation in equine synovial fluid, supporting its relevance in assessing 845 inflammatory conditions in horses [17]. Fibrinogen, in contrast, an acute phase protein that is always present 846 in blood samples, increases by 1-2 times with an inflammatory stimulus, and whose changes lag behind the 847 resolution of inflammation or infection [18]. It has been a long time since clinical treatments of OA focused on 848 improving joint pain symptoms rather than on the decline of the disease progression [19]. Despite the use of 849 many medications, both locally and systemically as well as topically, the management and treatment of equine 850 osteoarthritis remains a challenge [20].

851 Currently, the mainstay of intra-articular therapy focuses on alleviating the signs of disease through temporary 852 inflammation reduction, often achieved via corticosteroid (CS) injections [21]. Although corticosteroids have 853 a strong analgesic effect, they are also associated with multiple adverse effect such as promote cartilage 854 degradation, and inhibitory effects on collagen synthesis by chondrocytes [22]. For these reasons, new 855 approaches to the treatment of OA in horses are necessary. Cell therapy, such as platelet-rich plasma, has lately 856 emerged as a promising treatment option for various disorders, including osteoarthritis [23], and the field of 857 equine regenerative medicine is drawing increasing attention in the scientific community for its treatment 858 strategies for joint pathologies [24].

The aim of this study is to determine the effect of intra-articular injection of platelet-rich plasma (PRP) alone and combined with triamcinolone acetonide (TA) into the osteoarthritic (OA) fetlock on the changes in the levels of specific OA biomarkers synovial fluid (SF). For this purpose, eight biomarkers (Fibrinogen, Haptoglobin, MMP-2, MMP-9, Total Protein, IL-1 β , IL-6, and HIF-1 α) were evaluated. We hypothesized, that both PRP and TA+PRP treatments suppress inflammation and cartilage degradation.


864

865 2. Material and Methods

866 2.1. Study Design

14 thoroughbred racehorses were included in this study, ranging between 2 and 5 years, with a mean \pm SD age of 3.2 \pm 1.3 years. The horses were evaluated by two equine veterinarians, each with over 15 years of

- 869 experience in the racing industry working for the Racehorse Hospital at the Jockey Club of Turkey. Cases were
- 870 defined as horses having the following inclusion criteria; clinical evidence of osteoarthritis including effusion,
- pain on flexion and lameness localised to one limb/one fetlock joint only. Lameness, 2 to 3 grade was includedin this study.
- 873 Exclusion criteria were any fracture and history of infection associated with the joint, and any horse that was
- treated with any IA injection or other systematic anti-inflammatory therapy within 4 weeks before the inclusion
- 875 in the study. Passive flexion test and joint effusion was graded using a four-point scale ranging from normal to
- 876 severe (0=none, 1=mild, 2=moderate, 3=severe). Lameness was assessed when the horses trot in a straight line
- 877 on hard surfaces with digital flexion test (fetlock flexion test) and graded from 0 to 5 using the modified AAEP
- 878 grading scale.
- 879 Radiography of the fetlock included five standard projections, and additional projections were taken in different 880 cases. The standard radiographic views obtained were the following: lateromedial, dorso15° proximal-881 dorso45° proximolateral-palmarodistomedial dorso45° proximomedialpalmarodistal, oblique, 882 palmarodistolateral oblique, flexed lateromedial and flexed dorsopalmar projections. The radiographs assessed 883 including at least one of the following findings; periarticular osteophytes, capsular enthesophytes, loss of joint space, subchondral bone sclerosis/lysis of the proximal phalanx and/or the metacarpal condyle were assessed by 884 885 the veterinary surgeons of the jockey club.
- 886 Intra-articular injections were performed by passing a needle percutaneously into the joint, and synovial fluids
- 887 were aspirated prior to the injection of PRP or TA+PRP for each group, as shown in Figure 1.
- 888



- 900
- **901** Figure 1. Timeline for PRP and TA+PRP treatment groups in synovial fluid aspiration and injection.
- 902
- 903
- 904

905 2.2. Treatment

The selected horses were randomly divided into two groups. The group PRP received one single intra-articular 906 907 injection of PRP in the affected fetlock joint. The group TA+PRP received one intra-articular injection of 4 mg/2ml of TA (SINAKORT-A, ml/40 mg), followed by a single intra-articular PRP injection one week later in 908 909 the affected joint. Each joint received 1 mL of a platelet concentration of 1×10^{6} PLT/µL. After receiving the 910 intra-articular injections, all horses were instructed to have 24 hours of box rest. Following this rest period, 911 they were to engage in walking and trotting for a total of 20 minutes during the treatment period for both groups. If the horses did not exhibit signs of lameness, they gradually progressed to the previous training 912 913 regimens.

914 2.3. Synovial Fluid Sampling

All fetlock joints were aseptically prepared. Synovial fluid samples were aspirated from the affected fetlock
joint using a 21 G 0.80 x 40 mm needle with lateral palmar approach. SF sampling was performed only as pre
and post-treatment for each group (PRP and TA+PRP) as shown in Figure 1. Fluid was centrifuged at 3200
rpm for 5 min at 5–10°C. The supernatant was aspirated, and the pellet was discarded. The supernatant was
stored at -80° C until future analysis.

920 2.4. Platelet-Rich Plasma preparation

921 PRP was prepared from whole blood using the double centrifuge method reported by Tognoloni et al 2023. 922 After performing antisepsis, 85 ml of blood was collected from the horse by venipuncture of the jugular vein 923 using a 14-gauge (G), 2.10 mm x 45 mm orange catheter. The collected blood was drawn into two sterile 50 924 ml syringes and then transferred into 10 Vacutainer® tubes containing acid citrate-dextrose (ACD) solution. 925 PLT pellet was then resuspended in a volume of platelet-poor plasma to obtain a final platelet concentration 926 of 1×10^6 PLT/µL; PLT, counts were determined with a hemacytometer. The leukocyte concentration in the 927 PRP preparations was notably low: $0.38 \pm 0.16 \times 10^3/\mu$ L.

928 2.5. APPs measurement

929 APP concentrations in synovial fluid samples were measured using the Equinostic EVA1 diode array 930 spectrophotometer after being thawed at room temperature (RT) prior to sampling in all samples. Fibrinogen 931 and haptoglobin concentrations were determined via a turbidimetric 'latex-enhanced' method and an 932 immunoturbidometric method, respectively. The measurement of synovial fibrinogen, and haptoglobin 933 concentrations as well as the calibration of the equipment, were all performed according to the manufacturer's 934 guidelines.

936 2.6. Gelatin zymography for MMP-2 and MMP-9 assays

937

938 Gelatin zymography analysis was performed to evaluate the MMPs present in the synovial fluid. The test is 939 based on the ability of MMPs to degrade the gelatin contained in the substrate in which they are incubated and 940 separated, as MMP-2 and MMP-9 are two gelatinases. The zymography was conducted under non-reducing conditions; the samples were diluted in Loading Buffer containing 0.125 M Tris-HCl pH 6.8, 4% glycerol, 1% 941 942 SDS, and 0.125M Bromophenol Blue. DTT was not added, and the samples were incubated for 10 minutes at 943 room temperature. Following incubation, the samples were loaded onto the gel, and electrophoresis was 944 performed. After that, a triple wash was performed, each for 30 minutes, in a 2.5% Triton X-100 solution to 945 remove the SDS and allow the renaturation of the MMPs. Subsequently, the gel was transferred into the assay 946 buffer consisting of 50mM Tris-HCl (pH 7.5), 5mM CaCl₂, 0.2M NaCl, and 0.02% Brij-35, and incubated at 947 37°C for 20 hours. After the 20-hour period, the gel was first stained with 0.25% Coomassie Brilliant Blue R-948 250 (Sigma-Aldrich) for 1 hour and then destained for 30 minutes with a destaining solution composed of 30% 949 methanol, 10% acetic acid, and bidistilled water. Proteolysis was observed through the formation of a white 950 area on a blue background. Images were acquired every 5, 10, 15 and 30 minutes of destaining using the GS-951 800 Imaging System Scanner (Bio-Rad). The intensity of the bands related to the gelatinase activity was 952 quantified through densitometric analysis using the software Quantity One 4.5.0 (Bio-Rad).

953

954 2.7. Protein quantification

955

956 The total protein concentration in synovial fluid was measured using the Bradford assay (Bradford Protein 957 Assay Kit). It's based on the Coomassie Brilliant Blue G-250 dye binding to proteins, which causes a colour 958 change from reddish-brown to blue. The absorbance and 595 nm proportional to the protein concentration was 959 measured by using a plate spectrophotometer (Infinite® 200 Pro-Tecan, Mennedorf, Switzerland). BSA was 960 used as an external standard.

961 2.8. IL-1 β , IL-6 and HIF-1 α measuremet

962 Synovial fluid samples were thawed at room temperature (RT) prior to ELISA. Commercially available horse 963 IL-1B, IL-6 and HIF-1 α ELISA kits were used for the in vitro quantitative determination in synovial fluid. All 964 three kits were sandwich enzyme-linked immunosorbent assay (sELISA) and were processed according to the 965 manufacturer's instructions. The ELISA kits for the determination of IL-1B, IL-6 and HIF-1 α were validated 966 for use on equine SF using standard parallel and serial dilutions. Validation assays generated consistent results 967 in intra-assay and inter-assay comparisons. The intra-assay coefficient of variation (CV) was < 8% and the 968 inter-assay coefficient was <10% for IL-1B, IL-6 and HIF-1 α . Each sample was measured in duplicate.

The study involved two groups of racehorses: the PRP group and the TA+PRP group. Three statistical analyses 971 972 were conducted to assess treatment effects on biomarkers, according to the nature of the data. The quantitative 973 data are expressed as mean \pm SD or median and range as appropriate. The Shapiro-Wilk test was performed to 974 check the normality of the data. The data resulted in a normal distribution was assessed for homoscedasticity 975 and variance homogeneity by using Levene's test. Data with deviation from the normal distribution was 976 statistically tested using a non-parametric test (i.e., Kruskal-Wallis). ANOVA was used to compare pre- and 977 post-treatment levels of synovial biomarkers between PRP group and TA+PRP group. And also used for 978 analyzing pre- and post-treatment changes in synovial biomarkers within the group TA+PRP. The post-PRP 979 treatments were compared between the PRP and TA+PRP groups using independent sample T-tests or Mann-980 Whitney U tests, depending on data distribution and variance homogeneity. All analyses were performed using 981 JASP software (version 0.18.1), and a p-value < 0.05 was considered statistically significant for all tests.

982 **3.** Results

983 All synovial fluid samples were collected within 1 year from 14 horses (n = 14). A total of 14 MCPJs from 984 14 thoroughbred racehorses were included in this study, ranging between 2 and 5 years, with a mean \pm SD age 985 of 3.2 ± 1.3 years. There were 7 females and 7 males. Seven joints (right forelimb = 2; left forelimb = 5) from 986 7 horses were in group PRP, and 7 (right forelimb = 3; left forelimb = 4) from 7 horses were in group TA+PRP. 987 There were no differences in age (p = 0.53), sex (p = 0.28), or limb affected (p = 1.0) between group PRP and 988 group TA+PRP. Of the 14 cases, eight horses (57%) were lame in the left forelimb, and six horses (42%) were 989 lame in the right forelimb. In total, 11 of the horses (%79) were grade 2/5 lame, and 3 horses (%21) were grade 990 3/5 lame.

991 3.1. Fibrinogen and Haptoglobin Concentration


992 Fibrinogen levels in the PRP group remained constant before $(1.2\pm2.1 \text{ g/l})$ and after the treatment $(1.1\pm0.7 \text{ g/l})$ g/l) without showing significant changes. One-way ANOVA revealed a significant change in fibrinogen levels 993 994 over time in the TA+PRP group (Figure 2A). Pairwise comparison showed initially a significant decrease in 995 fibrinogen from pre-TA treatment (0.6±0.3 g/l) to post-TA treatment (0.3±0.2 g/l) (p-value = 0.04) and a 996 subsequent increase post-TA+PRP administration (0.9 ± 0.2 g/l) (post-TA vs. post-TA+PRP p-value = 0.002). 997 Levels of fibrinogen post-TA+PRP administration were also significantly higher when compared to the pre-998 TA levels (p-value = 0.04). Mann-Whitney test indicated significant differences when comparing fibrinogen 999 levels between the PRP and TA+PRP groups after the administration of PRP and TA, respectively, with the 1000 PRP group displaying higher fibrinogen levels (post-PRP vs. post-TA p-value = 0.03) as shown in Figure 2D.

1001 Haptoglobin levels in the PRP group did not significantly differ before $(2\pm2.7 \text{ g/l})$ and after the treatment 1002 $(1\pm0.7 \text{ g/l})$. ANOVA test, however, showed significant changes in the TA+PRP group (Figure 2B): multiple 1003 comparison found haptoglobin levels slightly decreasing (without statistical significance) from before TA 1004 treatment (0.8 ± 0.4 g/l) to after TA treatment (0.5 ± 0.2 g/l) and then increasing significantly after PRP 1005 administration (1.1 ± 0.5 g/l) (post-TA vs. post-TA+PRP p-value = 0.02), exceeding pre-TA levels (pre-TA vs 1006 post-TA+PRP p-value = 0.001). No statistically significant change between groups was found.

1007 3.2. *TP concentration*

For total protein, PRP group did not show significant differences between the pre-PRP ($12\pm8.3 \text{ mg/ml}$) and the post-PRP levels ($14.7\pm6.5 \text{ mg/ml}$). Within the TA+PRP group, concentrations of total protein (TP) were constantly decreasing throughout the duration of the study (Figure 2C), from the pre-TA levels (15.6 ± 7.4 mg/ml) to post-TA ($7.3\pm5.5 \text{ mg/ml}$) and to post-TA+PRP levels ($4\pm 2 \text{ mg/ml}$). Multiple comparison showed statistical significance between the levels of the pre-TA phase and the post-TA+PRP phase (p-value = 0.01). Mann-Whitney test between PRP and TA+PRP groups showed that TP levels in the PRP group post-PRP administration were significantly higher than in TA+PRP group post-TA+PRP administrations (p-value = 0.01)

- as shown in Figure 2E.
- 1016
- 1017
- 1018



```
1019
```

1020Figure 2. Bar plots showing the mean \pm SD of the concentration levels of three different protein biomarkers1021in SF. Figures 2A, 2B and 2C display the trends of fibrinogen, haptoglobin and total protein in the TA+PRP1022group at each time point: before TA treatment, after TA treatment and after PRP treatment. Figures 2D and 2E1023compare fibrinogen and total protein concentration between the TA+PRP group and the PRP group in their1024different treatment time. Bars with different letters indicate the presence of statistically significant differences1025(p-value < 0.05).</td>

1026 3.3. MMP-2 and MMP-9 expression

1027 In the statistical tests performed, no significant difference was found within and between the groups for the 1028 MMP-2 and MMP-9 biomarkers. The MMP-2 levels detected in the PRP group were 0.8 ± 0.4 , pre-PRP and 1029 0.8 ± 0.1 , post-PRP, while in the TA+PRP group where 0.6 ± 0.2 pre-TA, 0.9 ± 0.6 post-TA and 0.9 ± 0.3 post-1030 TA+PRP. The MMP-9 levels detected in the PRP group were 0.5 ± 0.1 , pre-PRP and 0.4 ± 0.1 post-PRP, while 1031 in the TA+PRP group where 0.5 ± 0.6 pre-TA, 0.4 ± 0.2 post-TA and 0.3 ± 0.1 post-TA+PRP.

1032 3.4. Zymography MMP-2 and MMP-9

The zymography analysis demonstrated distinct enzymatic activities for both MMP-2 and MMP-9 in the SF samples (Figure 3). Clear bands were observed at approximately 72 kDa and 92 kDa, corresponding to the proforms of MMP-2 and MMP-9, respectively. Additionally, faint bands at around 62 kDa for MMP-2 and 82 kDa for MMP-9 indicated the presence of active forms of these enzymes. The zymography indicates that MMP-2 may be more active or abundant in certain samples, which resulted in a constant level before and after treatments. In contrast, MMP-9 activity modulated over the treatment period.

1039

1040




Figure 3. Zymographic analysis of MMP-2 and MMP-9 activity following the TA and PRP administrations. This figure demonstrates zymography results illustrating the activity levels of MMP-2 and MMP-9 in synovial fluid samples from horses treated with TA and platelet-rich plasma PRP. Bands indicate enzymatic activity, with brighter bands representing areas where the enzymes actively degraded the gel substrate.

- 1051
- 1052

1053 3.5. IL-1 β , IL-6, and HIF-1 α expression levels in synovial fluid

1054 In this investigation, we used ELISA test to measure the expression of inflammatory cytokines and hypoxia-1055 related biomarkers in synovial fluid, such as IL-1 β , IL-6, and HIF-1 α . These indicators were chosen for their 1056 possible involvement in inflammatory processes and tissue response under hypoxic circumstances. Our 1057 research found no significant differences in IL-1 β , IL-6, or HIF-1 α expression levels among treatment groups 1058 or time points. This lack of detectable changes might mean that the expression of these biomarkers in synovial 1059 fluid is unaffected by the therapies used or that ELISA's sensitivity under our study conditions was insufficient 1060 to detect minimal fluctuations.

1061 4. Discussion

1062 In the present study, five synovial biomarkers revealed variable degrees of susceptibility to OA and intra-1063 articular therapeutic approaches. We aimed to see if PRP and TA+PRP treatments could regulate the 1064 inflammatory or degenerative processes associated with OA by measuring changes in biomarker concentrations. The findings show that whereas PRP alone did not significantly modify biomarker levels, the
 combination of TA and PRP resulted in significant changes indicating a potential synergistic effect in
 controlling OA-associated inflammation.

1068 Fibrinogen, essential plasma protein for blood clothing and is found in the inflamed tissues including the joints 1069 [25,26]. Corticosteroids are known as their potential anti-inflammatory effect. In this study, in the TA+PRP 1070 group, after the administration of TA into the joint, the authors observed a significant reduction in fibrinogen 1071 concentration. These findings agree with the studies that showed a reduction of fibrinogen levels in the active 1072 inflammation, as well as in the affected joint following corticosteroid use [25,27]. However, PRP 1073 administration following the TA injection, the fibrinogen concentration was significantly increased. Some 1074 studies showed that PRP reduce the fibrinogen levels, in contrast to our study [26]. PRP naturally contains 1075 various plasma proteins, whose main functions are carrier, immunity, blood clothing as well as that activate 1076 fibrinogen to form fibrin scaffolds, induce chondrocyte proliferation and differentiation, and promote cartilage 1077 damage repair[28,29]. Surprisingly, in the PRP group, there was no significant difference at each time point. 1078 This brings the question about the TA+PRP group the level of fibrinogen increase following the PRP injection, 1079 while in the PRP group, it does not. This is most likely because fibrinogen has a multifaceted role in tissue 1080 injury and inflammation [30]. Since fibrinogen has common and ancient domains that play pivotal roles in the 1081 transition from inflammation to tissue repair, this might explain the increase observed with PRP followed by 1082 preconditioned TA [31].

1083 Haptoglobin (Hp) is part of the acute phase response to inflammation, which is considered a biomarker in 1084 clinical practice. Hp was identified in the synovial fluid of horses with osteoarthritis (OA), demonstrating the 1085 ability to serve as a biomarker for joint disease an has been linked to OA severity, particularly knee OA [32]. 1086 The presence of Hp in joints observed, supported by the studies, indicating that Hp is produced locally in 1087 inflamed joints [17]. Previous research, such as that conducted by Stevens et al., demonstrated that 1088 chondrocytes in bovine cartilage might produce haptoglobin [33]. Similarly, Smeets et al. and Rosenkranz et 1089 al. found Hp expression in arthritic tissues in rats and synovial fluid from juvenile idiopathic arthritis in 1090 humans, respectively [34,35]. This cross-species reliability in Hp's activity highlights its likely significance in 1091 OA diagnostics and as an inflammatory marker in joint disease. Within the PRP group, there was no significant 1092 difference in Hp concentration over time, while in the TA+PRP group, there were significant increases between 1093 each time point. Hp concentration was also found in healthy equine joints as 0.004 ± 0.004 (g/dL) [36]. In this 1094 research the concentration of haptoglobin was 0.98 ± 1.04 (g/L). This might indicate haptoglobin serves as a 1095 OA biomarker in accordance also with the abovementioned studies. Interestingly, haptoglobin and fibrinogen 1096 showed similar trends in our study, with both markers declining following the TA administration post-1097 treatment. The temporary elevation in fibrinogen and haptoglobin following PRP injection might be attributed 1098 to local synthesis by inflamed joint tissues, potentially as an acute response to inflammation. Moreover, PRP 1099 rich in leukocytes have been shown to cause a significantly greater acute inflammatory response [37,38]. 1100 However, this excessive acute inflammatory response was not seen in this research, most likely due to our 1101 preparation was poor in leukocytes.

1102 Synovial fluid TP content has been reported to be higher in OA joints than in normal joints [39]. In our study, 1103 the TA+PRP group showed a significant reduction in TP levels at each time points (p = 0.003). In contrast, the 1104 PRP-only group showed an increase in TP concentration post-treatment. Statistically significant differences 1105 were observed post-PRP treatment in both PRP-only and TA+PRP groups (p = 0.001). Chen et al. found a 1106 significant decrease in TP concentration after PRP injection [32]; however, in our study, this decrease was 1107 noted in the TA+PRP group, not after direct PRP injection alone. The TP increase in the PRP-only group may 1108 be related to the fact that PRP products naturally contain total proteins [6,29] and PRP can also induce an acute 1109 inflammatory response in the joint, thus changes in total protein were observed in response to intra-articular 1110 PRP injection. This changes aligns with findings from Moraes et al. and Textor et al. [40,41].

1111 Nevertheless, this TP increase appears to have no lasting clinical effect, as no adverse reactions to PRP 1112 administration were observed. This further supports that PRP remains a safe therapeutic option for intra-1113 synovial administration [28].

Matrix metalloproteinases are enzymes capable of matrix digestion; they are normal constituents of the matrix but are present in an inactive form. In the pathogenesis of the joint disease, the activation of MMP-9 is associated with an increase in MMP-2 expression [42]. MMP-9 is produced and released into SF by chondrocytes and synoviocytes in joint disease in horses but not in clinically normal joints [43]. In our study, there were expressions of both MMP-2 and MMP-9. Similar to findings that found in this study supported by Gaudi et al. [44]. However, the expression of MMPs did not result in significant changes statistically.

1120 PRP exposure did not result in significant changes in matrix metalloproteinases (MMPs) gene expression, 1121 specifically MMP-2 and MMP-9. Our finding aligns with previous research by Hur et al., which also reported 1122 that PRP did not significantly reduce MMP expression [45]. MMPs are known also released by platelets on a 1123 platelets dose-dependent basis, increasing the total concentration of MMPs [29]. Although we observed no 1124 statistically significant differences in MMP-2 and MMP-9 concentrations in the PRP group following treatment, a notable trend in MMP-9 levels showed a gradual decline in zymographic assessment in the 1125 1126 TA+PRP group. This suggests that TA+PRP may have a moderating effect on MMP-9 activity, although further 1127 research is needed to understand the mechanisms involved. The decrease in MMPs by PRP was confirmed by 1128 various researchers, while others mention either no effect or a decrease in these parameters [46–48]. Given the 1129 small sample size in our study, future investigations with larger sample sizes are essential to elucidate the full 1130 spectrum of MMP activity in PRP treatments, especially in combination with corticosteroids like TA.

1131 It was difficult to draw definitive conclusions regarding IL-6 and IL-1 β cytokine levels or the effects of the 1132 treatments on these biomarkers due to their low concentrations. It is worth noting that synovial fluid (SF) 1133 provides a close reflection of individual joint status. However, SF aspiration involves greater risk than other 1134 sample types like urine or serum, and biomarker concentrations in SF may vary significantly based on the level 1135 of active joint inflammation [49]. This variability may result from dilution or "washout" effects, particularly 1136 in cases of high joint effusion [49]. However, 2 out of 14 horses, a significant increase in pro-inflammatory 1137 cytokines was observed, which subsequently decreased following TA and PRP treatments. Only these two horses had an effusion score of 0, whereas the remaining horses had scores of 2 or higher (data not shown).
This difference suggests that higher effusion scores may dilute synovial biomarkers, making them harder to
detect. This observation aligns with previous studies indicating that excessive joint fluid can mask biomarker
levels through dilution and altered clearance rates [7,50,51]

1142 Interestingly, haptoglobin levels were also notably higher in these same two horses that showed increased pro-1143 inflammatory cytokines. A possible relationship between inflammatory cytokines and haptoglobin levels is in 1144 agreement with the study that authors suggest an increase in haptoglobin could be influenced by IL-1 β , which 1145 is known to stimulate its production [33,52]. Samut et al. demonstrated that IL-6 significantly enhances 1146 haptoglobin expression and activity produced in response to IL-1ß activity [53]. This suggests that the elevated 1147 haptoglobin levels in these horses' synovial fluid may partly reflect upstream increases in IL-1β and IL-6, 1148 which might indicate haptoglobin's potential role as a biomarker of inflammation in OA [17]. For instance, it 1149 is well known that increased activity and amounts of MMPs contribute to the metabolic imbalance in the 1150 articular cartilage in most OA patients [54] Haptoglobin might act as a nonspecific inhibitor of MMP-2 and 1151 MMP-9 [55] which constitute the gelatinase subgroup and are capable of catabolising the macromolecules in 1152 the extracellular matrix [56]. Therefore, it is reasonable to deduce that the increased concentration of 1153 haptoglobin in the SF of OA patients probably represents feedback from the enhanced MMP activity to protect 1154 the macromolecules in the extracellular matrix from being broken down excessively [52].

1155

1156 Conclusion

PRP, when applied alone without TA, does not cause significant changes in biomarkers, nor does it induce any inflammation, thereby demonstrating a safe profile within the joint. Sequential use of TA and PRP, however, has shown improved effects. This suggests that PRP produces a more controlled inflammatory response when administered in a joint where inflammation is reduced. Further research with a larger sample size and additional

- time points is needed to examine the long-term effects of these two treatments on synovial biomarkers in OA.
- 1162

1163 References

1164

- McIlwraith CW. Current concepts in equine degenerative joint disease. J Am Vet Med Assoc.
 1982;180(3):239-250.
- 1167 2. Ma TW, Li Y, Wang GY, et al. Changes in Synovial Fluid Biomarkers after Experimental Equine
 1168 Osteoarthritis. J Vet Res. 2017;61(4):503-508. doi:10.1515/jvetres-2017-0056
- JEFFCOTT LB, ROSSDALE PD, FREESTONE J, FRANK CJ, TOWERS-CLARK PF. An assessment
 of wastage in Thoroughbred racing from conception to 4 years of age. Equine Vet J. 1982;14(3):185-
- 1171 198. doi:10.1111/j.2042-3306.1982.tb02389.x

- Ehrle A, Lischer CJ, Lasarzik J, Einspanier R, Bondzio A. Synovial Fluid and Serum Concentrations of
 Interleukin-1 Receptor Antagonist and Interleukin-1β in Naturally Occurring Equine Osteoarthritis and
 Septic Arthritis. J Equine Vet Sci. 2015;35(10):815-822. doi:10.1016/j.jevs.2015.07.023
- 1175 5. McILWRAITH CW. Use of synovial fluid and serum biomarkers in equine bone and joint disease: a
 1176 review. Equine Vet J. 2010;37(5):473-482. doi:10.2746/042516405774480102
- 1177 6. Ruiz-Romero C, Blanco FJ. Proteomics role in the search for improved diagnosis, prognosis and
 1178 treatment of osteoarthritis. Osteoarthritis Cartilage. 2010;18(4):500-509.
 1179 doi:10.1016/j.joca.2009.11.012
- 1180 7. de Grauw JC, van de Lest CHA, van Weeren PR. Inflammatory mediators and cartilage biomarkers in
 1181 synovial fluid after a single inflammatory insult: a longitudinal experimental study. Arthritis Res Ther.
 1182 2009;11(2):R35. doi:10.1186/ar2640
- Garvican ER, Vaughan-Thomas A, Innes JF, Clegg PD. Biomarkers of cartilage turnover. Part 1:
 Markers of collagen degradation and synthesis. The Veterinary Journal. 2010;185(1):36-42.
 doi:10.1016/j.tvjl.2010.04.011
- 1186 9. Van Pelt RW, Riley WF. Tarsal hydrarthrosis in the horse: response to intra-articular injection of
 1187 synthetic steroids. Can Vet J. 1969;10(5):130-135.
- 1188 10. Gruys E, Toussaint MJM, Niewold TA, Koopmans SJ. Acute phase reaction and acute phase proteins.
 1189 J Zhejiang Univ Sci B. 2005;6(11):1045-1056. doi:10.1631/jzus.2005.B1045
- 1190 11. Sipe JD. Acute-phase proteins in osteoarthritis. Semin Arthritis Rheum. 1995;25(2):75-86.
 1191 doi:10.1016/s0049-0172(95)80020-4
- 1192 12. Jeng GW, Wang CR, Liu ST, et al. Measurement of synovial tumor necrosis factor-alpha in diagnosing
 emergency patients with bacterial arthritis. Am J Emerg Med. 1997;15(7):626-629. doi:10.1016/s07356757(97)90173-x
- 1195 13. Petersen HH, Nielsen JP, Heegaard PMH. Application of acute phase protein measurements in veterinary clinical chemistry. Vet Res. 2004;35(2):163-187. doi:10.1051/vetres:2004002
- 1197 14. Crisman M V, Scarratt WK, Zimmerman KL. Blood proteins and inflammation in the horse. Vet Clin
 1198 North Am Equine Pract. 2008;24(2):285-297, vi. doi:10.1016/j.cveq.2008.03.004
- Pihl TH, Andersen PH, Kjelgaard-Hansen M, Mørck NB, Jacobsen S. Serum amyloid A and haptoglobin
 concentrations in serum and peritoneal fluid of healthy horses and horses with acute abdominal pain.
 Vet Clin Pathol. 2013;42(2):177-183. doi:10.1111/vcp.12031
- 1202 16. HULTÉN C, GRÖNLUND U, HIRVONEN J, et al. Dynamics in serum of the inflammatory markers
 1203 serum amyloid A (SAA), haptoglobin, fibrinogen and α 2 -globulins during induced noninfectious
 1204 arthritis in the horse. Equine Vet J. 2002;34(7):699-704. doi:10.2746/042516402776250405
- 1205 17. Barrachina L, Remacha AR, Soler L, et al. Acute phase protein haptoglobin as inflammatory marker in serum and synovial fluid in an equine model of arthritis. Vet Immunol Immunopathol. 2016;182:74-78.
 1207 doi:10.1016/j.vetimm.2016.10.005

- NUNOKAWA Y, FUJINAGA T, TAIRA T, et al. Evaluation of Serum Amyloid A Protein as an Acute Phase Reactive Protein in Horses. Journal of Veterinary Medical Science. 1993;55(6):1011-1016.
 doi:10.1292/jvms.55.1011
- 1211 19. Yao Q, Wu X, Tao C, et al. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal
 1212 Transduct Target Ther. 2023;8(1):56. doi:10.1038/s41392-023-01330-w
- 1213 20. Frisbie DD. Future directions in treatment of joint disease in horses. Veterinary Clinics of North
 1214 America Equine Practice. 2005;21(3):713-724. doi:10.1016/j.cveq.2005.07.001
- 1215 21. Goodrich LR, Nixon AJ. Medical treatment of osteoarthritis in the horse A review. Veterinary
 1216 Journal. 2006;171(1):51-69. doi:10.1016/j.tvjl.2004.07.008
- 1217 22. Souza MV de. Osteoarthritis in horses Part 2: a review of the intra-articular use of corticosteroids as a
 1218 method of treatment. Brazilian Archives of Biology and Technology. 2016;59(0). doi:10.1590/16781219 4324-2016150025
- Moussa M, Lajeunesse D, Hilal G, et al. Platelet rich plasma (PRP) induces chondroprotection via
 increasing autophagy, anti-inflammatory markers, and decreasing apoptosis in human osteoarthritic
 cartilage. Exp Cell Res. 2017;352(1):146-156. doi:10.1016/j.yexcr.2017.02.012
- 1223 24. Broeckx S, Zimmerman M, Crocetti S, et al. Regenerative therapies for equine degenerative joint
 1224 disease: A preliminary study. PLoS One. 2014;9(1). doi:10.1371/journal.pone.0085917
- 1225 25. Seligsohn U, Rapaport SI, Shen SM, Kuefler PR. Effect of corticosteroids upon fibrinogen metabolism
 1226 in rabbits. Thromb Diath Haemorrh. 1973;30(3):531-540.
- Pourkarim R, Farahpour MR, Rezaei SA. Comparison effects of platelet-rich plasma on healing of
 infected and non-infected excision wounds by the modulation of the expression of inflammatory
 mediators: experimental research. European Journal of Trauma and Emergency Surgery.
 2022;48(4):3339-3347. doi:10.1007/s00068-022-01907-0
- 1231 27. van Zaane B, Nur E, Squizzato A, et al. Systematic review on the effect of glucocorticoid use on
 procoagulant, anti-coagulant and fibrinolytic factors. Journal of Thrombosis and Haemostasis.
 1233 2010;8(11):2483-2493. doi:10.1111/j.1538-7836.2010.04034.x
- 1234 28. Xiong Y, Gong C, Peng X, et al. Efficacy and safety of platelet-rich plasma injections for the treatment
 1235 of osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Front Med
 1236 (Lausanne). 2023;10. doi:10.3389/fmed.2023.1204144
- 1237 29. Everts PA, Lana JF, Alexander RW, et al. Profound Properties of Protein-Rich, Platelet-Rich Plasma
 1238 Matrices as Novel, Multi-Purpose Biological Platforms in Tissue Repair, Regeneration, and Wound
 1239 Healing. Int J Mol Sci. 2024;25(14). doi:10.3390/ijms25147914
- 1240 30. Luyendyk JP, Schoenecker JG, Flick MJ. The multifaceted role of fibrinogen in tissue injury and
 1241 inflammation. Blood. 2019;133(6):511-520. doi:10.1182/blood-2018-07-818211
- 1242 31. Flick MJ, Du X, Degen JL. Fibrin(ogen)-αMβ2 Interactions Regulate Leukocyte Function and Innate
 1243 Immunity In Vivo. Exp Biol Med. 2004;229(11):1105-1110. doi:10.1177/153537020422901104

- 1244 32. Chen CPC, Cheng CH, Hsu CC, Lin HC, Tsai YR, Chen JL. The influence of platelet rich plasma on
 1245 synovial fluid volumes, protein concentrations, and severity of pain in patients with knee osteoarthritis.
 1246 Exp Gerontol. 2017;93:68-72. doi:10.1016/j.exger.2017.04.004
- 1247 33. Stevens AL, Wishnok JS, Chai DH, Grodzinsky AJ, Tannenbaum SR. A sodium dodecyl sulfate-1248 polyacrylamide gel electrophoresis-liquid chromatography tandem mass spectrometry analysis of 1249 bovine cartilage tissue response to mechanical compression injury and the inflammatory cytokines 1250 tumor necrosis factor α and interleukin-1β. Arthritis Rheum. 2008;58(2):489-500. 1251 doi:10.1002/art.23120
- 34. Smeets MB, Fontijn J, Kavelaars A, Pasterkamp G, De Kleijn DPV. The acute phase protein haptoglobin
 is locally expressed in arthritic and oncological tissues. Int J Exp Pathol. 2003;84(2):69-74.
 doi:10.1046/j.1365-2613.2003.00336.x
- 1255 35. Rosenkranz ME, Wilson DC, Marinov AD, et al. Synovial fluid proteins differentiate between the
 1256 subtypes of juvenile idiopathic arthritis. Arthritis Rheum. 2010;62(6):1813-1823. doi:10.1002/art.27447
- 1257 36. Basile RC, Ferraz GC, Carvalho MP, et al. Physiological Concentrations of Acute-Phase Proteins and
 1258 Immunoglobulins in Equine Synovial Fluid. J Equine Vet Sci. 2013;33(3):201-204.
 1259 doi:10.1016/j.jevs.2012.05.075
- 1260 37. Dragoo JL, Braun HJ, Durham JL, et al. Comparison of the acute inflammatory response of two
 1261 commercial platelet-rich plasma systems in healthy rabbit tendons. American Journal of Sports
 1262 Medicine. 2012;40(6):1274-1281. doi:10.1177/0363546512442334
- 38. Braun HJ, Kim HJ, Chu CR, Dragoo JL. The effect of platelet-rich plasma formulations and blood
 products on human synoviocytes: implications for intra-articular injury and therapy. Am J Sports Med.
 2014;42(5):1204-1210. doi:10.1177/0363546514525593
- 1266 39. Davis ES. Synovial Fluid Analysis in Patients with Osteoarthritis Requiring Total Joint Arthroplasty.
 1267 Vol 1.; 2018. http://surgeryresearchjournal.com
- 40. Paula A, Moraes L, Moreira JJ, et al. Article Short-and Long-Term Effects of Platelet-Rich Plasma upon
 Healthy Equine Joints: Clinical and Laboratory Aspects.
- 1270 41. Textor JA, Willits NH, Tablin F. Synovial fluid growth factor and cytokine concentrations after intra1271 articular injection of a platelet-rich product in horses. Veterinary Journal. 2013;198(1):217-223.
 1272 doi:10.1016/j.tvjl.2013.07.020
- 42. Garner B, Stoker A, Kuroki K, Evans R, Cook CR, Cook J. Using Animal Models in Osteoarthritis
 Biomarker Research. Journal of Knee Surgery. 2011;24(04):251-264. doi:10.1055/s-0031-1297361
- 1275 43. Clegg PD. Investigating the efficacy of articular medications in the horse: The science behind clinical
 1276 practices. Equine Vet J. 2010;42(6):484-486. doi:10.1111/j.2042-3306.2010.00210.x
- 44. Gaudin P, Razakaboay M, Surla A, et al. A study of metalloproteinases in fifty joint fluid specimens.
 Rev Rhum Engl Ed. 1997;64(6):375-381.

- Hur CI, Park C, Li H, et al. Effect of Autologus Platelet-Rich Plasma on IL-6, MMP-3 and MCP-1
 Expression in Synoviocytes from Osteoarthritic Patients Knees. Open Journal of Regenerative
 Medicine. 2014;03(03):64-72. doi:10.4236/ojrm.2014.33008
- van Buul GM, Koevoet WLM, Kops N, et al. Platelet-Rich Plasma Releasate Inhibits Inflammatory
 Processes in Osteoarthritic Chondrocytes. Am J Sports Med. 2011;39(11):2362-2370.
 doi:10.1177/0363546511419278
- 1285 47. Sundman EA, Cole BJ, Karas V, et al. The Anti-inflammatory and Matrix Restorative Mechanisms of
 1286 Platelet-Rich Plasma in Osteoarthritis. Am J Sports Med. 2014;42(1):35-41.
 1287 doi:10.1177/0363546513507766
- 48. Cavallo C, Filardo G, Mariani E, et al. Comparison of Platelet-Rich Plasma Formulations for Cartilage
 Healing. Journal of Bone and Joint Surgery. 2014;96(5):423-429. doi:10.2106/JBJS.M.00726
- 49. C. Wayne McIlwraith DDFCEKPR van W. Joint Disease In The Horse. In: Joint Disease in the Horse.
 Elsevier; 2016:iii. doi:10.1016/b978-1-4557-5969-9.01001-9
- 1292 50. Kraus VB, Huebner JL, Fink C, et al. Urea as a passive transport marker for arthritis biomarker studies.
 1293 Arthritis Rheum. 2002;46(2):420-427. doi:10.1002/art.10124
- 1294 51. Myers SL, Brandt KD, Eilam O. Even low-grade synovitis significantly accelerates the clearance of
 protein from the canine knee: implications for measurement of synovial fluid "markers" of osteoarthritis.
 Arthritis Rheum. 1995;38(8):1085-1091. doi:10.1002/art.1780380810
- 1297 52. Liao W, Li Z, Zhang H, Li J, Wang K, Yang Y. Proteomic Analysis of Synovial Fluid as an Analytical
 1298 Tool to Detect Candidate Biomarkers for Knee Osteoarthritis. Vol 8.; 2015. www.ijcep.com/
- 1299 53. Samut G, Dinçer F, Özdemir O. The effect of isokinetic and aerobic exercises on serum interleukin-6
 1300 and tumor necrosis factor alpha levels, pain, and functional activity in patients with knee osteoarthritis.
 1301 Mod Rheumatol. 2015;25(6):919-924. doi:10.3109/14397595.2015.1038425
- 1302 54. MURPHY G, HEMBRY RM, HUGHES CE, FOSANG AJ, HARDINGHAM TE. Role and regulation
 1303 of metalloproteinases in connective tissue turnover. Biochem Soc Trans. 1990;18(5):812-815.
 1304 doi:10.1042/bst0180812
- 1305 55. Schulze Willbrenning G, Hiss S, Theune C, Mielenz M, Schellander K, Sauerwein H. Gelatinase
 1306 activities and haptoglobin concentrations in healthy and in degenerative articular cartilage of pigs. J
 1307 Anim Physiol Anim Nutr (Berl). 2010;94(6):757-766. doi:10.1111/j.1439-0396.2009.00958.x
- 1308 56. Birkedal-Hansen H, Moore WGI, Bodden MK, et al. Matrix Metalloproteinases: A Review. Critical
 1309 Reviews in Oral Biology & Medicine. 1993;4(2):197-250. doi:10.1177/10454411930040020401
- 1310

1311

1312 GENERAL DISCUSSION

Osteoarthritis (OA) is a common disease in equine patients, causing up to 60% of all lameness cases. In current
 equine practice, the diagnosis is commonly based on clinical signs, such as joint effusion, lameness, and

1315 synovial fluid parameters, combined with diagnostic imaging evaluation. The treatment of OA frequently 1316 remains uncertain whether a particular therapy is having its effect by simply relieving the symptomatic pain 1317 associated with the joint disease, or whether it has a positive effect on the joint environment. Today, multiple 1318 treatments on the market to reduce symptoms of OA for equine patients such as orthobiologics as well as 1319 conventional treatment options like intra-articular corticosteroid or hyaluronic acid, used separately or in 1320 combination. The PhD thesis evaluated corticosteroids (triamcinolone acetonide) and orthobiologics (Platelet-1321 rich Plasma) use in fetlock joint OA and their effectiveness in vitro and in vivo studies. In vitro, TA showed 1322 adverse effects on chondrocytes, with a significant decrease in viability, as observed in the other studies. 1323 However, the combined use of TA and PRP increased cell viability, indicating a protective effect of PRP against 1324 cytotoxicity. PRP has also been reported to protect fibroblast cell types, including chondrocytes, against drug 1325 toxicity. Treatment with intra-articular PRP following to TA, showed promising improvement in clinical effect. 1326 Additionally, it is found that fibrinogen and haptoglobin levels were affected by treatment, especially in the 1327 TA+PRP group. Fibrinogen levels decreased after TA treatment and increased post-PRP administration, 1328 suggesting a reparative response. Haptoglobin levels increased post-TA+PRP administration, suggesting the 1329 combined treatment influences acute-phase proteins associated with inflammation in osteoarthritic joints. Total 1330 protein concentrations decreased, suggesting a sustained anti-inflammatory effect. MMP-9 expression were 1331 decreased by the TA+PRP treatment, that might indiciate combining these to treatment possible decreasing 1332 cartilage degradation.

1333 This PhD thesis had some limitations. The first limitation was that treatment protocols were different between 1334 groups. In vitro, PRP was added concomitantly with TA-treated chondrocytes, whereas in vivo, PRP was 1335 administered one week after TA. This timing also may have influenced the clinical results. However, the in 1336 vivo study was conducted on horses with OA symptoms, while the in vitro study used healthy chondrocytes 1337 treated with TA. Additionally, following the effects of TA for one week on chondrocytes in vitro is 1338 challenging, as we observed cytotoxicity even at lower doses. The second limitation, horses with similar 1339 pathologies may exhibit individual response to treatment. The therapeutic effects may also be influenced by 1340 the horses' working discipline and post-treatment exercise protocols.

The third limitation, blinded and placebo-controlled study not performed. In the horse, there has been a lack of good randomized controlled trials investigating the efficacy of articular therapeutics, most likely because they are difficult and expensive to perform. However, it is important to realize this lack of a placebo-controlled group and other objective measures may lead to erroneous conclusions, hence potentially treatment of many horses with ineffective medications over a long time period. Thus, the horses in the control group are at risk of suffering from joint-related pain throughout the study period. Besides that, training day loss in the racing industry and its caused economic burden.

The fourth limitation states that the limited number of horses used in the study could impact the assessment of the therapy's efficacy and any observed changes in synovial biomarkers. A limited sample size may limit the study's power in statistics, making it more difficult to identify meaningful variations in treatment effects and restricting the ways that the results may be applied. Individual response differences can have a more significant impact on the results of studies with fewer horses, thus overestimating or underestimating the effectiveness of
the treatment. Because individual biological variability may obscure the effects of treatment, a limited sample
size for synovial biomarkers may make it more difficult to detect modest biochemical changes linked to
inflammation or healing.

Overall, this is the first study to assess the combined effects of triamcinolone acetonide (TA) and platelet-rich plasma (PRP) on synovial biomarkers and equine cartilage cells, providing information regarding its possible therapeutic use in equine osteoarthritis (OA). While PRP alone had no influence on biomarker levels, it showed its safety profile when administered alone in the joint. The combination of TA and PRP significantly controlled inflammation-related biomarkers, particularly fibrinogen and haptoglobin, indicating a viable strategy for treating OA-affected joints. Although MMP-2 levels remained stable, the steady decline of MMP-9 suggests TA+PRP as a promising method for longer effects on pain and lameness reduction. More clinical trials with numerous PRP injections and longer follow-up are needed to better understand the long-term advantages and safety of combining TA and PRP in OA therapy for horse athletes.